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11 
Glycogen storage diseases (GSD) or glycogenoses are a group of inherited metabolic disorders, 
caused by enzyme defects that regulate glycogen degradation and (paradoxically) glycogen 
synthesis (figure 1). These disorders primarily involve liver and/or muscle, although rare 
neurological disorders have been described. GSD are denoted by Roman numeral, or by another 
synonym which is based on the deficient enzyme or the name of the author of the first 
description (Laforêt et al 2012). The first case of glycogen storage disease type III (GSDIII) 
was reported in 1928 by Van Creveld who described two patients (Snapper & Van Creveld 
1928), and later Van Creveld proved by enzymatic analysis that these patients actually had 
GSDIII (Van Creveld & Huijing 1964). In 1952, Illingworth and Cori demonstrated excessive 
amounts of abnormally structured glycogen in liver and muscle tissue of a GSDIII patient 
(Illingworth & Cori 1952). Analysis of the abnormal glycogen showed that the molecule had 
short outer chains. Therefore, the glycogen was classified as phosphorylase-limit dextrin, and 
thus a deficiency of amylo-1,6-glucosidase was predicted – which was confirmed in 1956 
(Illingworth et al 1956). 
The debranching enzyme consists of two active centres that catalyse one of the final 
steps in the conversion of glycogen to glucose (Bates et al 1975). Before the debranching 
enzyme starts to act, a phosphorylase enzyme breaks four glucose molecules off the glycogen 
molecule to form limit dextrin (Newgard et al 1989). In unaffected cells the first active centre 
of the debranching enzyme, 1,4-glucan-4-D-glucosyltransferase, transports the outer three 
glucose molecules of limit dextrin to another chain. Thereafter, the second active centre, 
amylo-1,6-glucosidase, releases the last glucose molecule (Lui et al 1991). In order to establish 
the diagnosis of GSDIII, mutation analysis can be performed or the debranching enzyme 
activity can be measured in white blood cells, muscle, and liver tissue. Upon pathologic 
examination, liver tissue composes of enlarged hepatocytes containing large amounts of limit 
dextrin. Also, periportal fibrosis and fibrous septa are usually present, particularly in specimens 
obtained from adult patients. 
Four subtypes of GSDIII have been described, the most common form being type IIIa 
which affects 80% of the GSDIII patients. As GSDIIIa affects both liver, cardiac and skeletal 
muscle tissue, this subtype is also known as the hepatic-myopatic subtype. The other common 
subtype is GSDIIIb, affecting 15% of the GSDIII patients. This form of GSDIII is also called 
the hepatic subtype as in these patients only the liver is affected. Furthermore, there are the two 
very rare subtypes: GSDIIIc and GSDIIId. In GSDIIIc, there is an active 1,4-glucan-4-D-
glucosyltransferase center, but amylo-1,6-glucosidase is deficient. In IIId there is a normal 
amylo-1,6-glucosidase activity, but 1,4-glucan-4-D-glucosyltransferase is deficient in both 
liver and muscle tissue. GSDIIId has been described in larger numbers than GSDIIIc, but still 
both subtypes are considered very rare (Ding et al 1990). 
GSDIII is an autosomal recessive disorder, in which a mutation in the AGL gene 
(located at 1p21), causes defiency of the debranching enzyme. As reported by Bao et al in 
1996, the human AGL gene is 85 kb in size with 35 exons. In 1997 Bao et al recognized the 
presence of six different isoforms that differ in the 5’ end by using several cryptic splice sites 
upstream of the translation initiation site, which allows the inclusion or removal of exons. 
Isoform 1 is the generalized form present in the liver, (skeletal and cardiac) muscle, and the 
kidneys. Isoforms 2, 3, and 4 are only present in skeletal and cardiac muscle tissue. These 
isoforms are formed as a result of alternative splicing or of a difference in transcription start 
points. Isoform 1 contains exons 1 and 3; isoforms 2, 3, and 4 start with exon 2. Isoforms 1 
through 4 all contain exon 3 which includes the normal initiation codon for protein translation. 
Exons 4-35 are present in all isoforms (Bao et al 1996; Bao et al 1997). The glycogen binding 
site is encoded by exons 31 and 32 and the active site is encoded by exons 6, 13, 14, and 15 
(Elpeleg 1999). 
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Figure 1. Simplified scheme of the glycogenolysis and glycolysis. (Laforêt et al 2012). The GSD and their 
respective enzyme deficiencies are: GSD 0 = glycogen synthase; GSD I = glucose-6-phosphatase; GSD II = α-
glucosidase; GSD III = debranching enzyme; GSD IV = branching enzyme; GSD V = myophosphorylase; GSD 
VI = liver phosphorylase; GSD VII = phosphofructokinase; GSD IX = phosphorylase-b-kinase; GSD X = 
phosphoglycerate mutase; GSD XI = lactate dehydrogenase; GSD  XII = fructose-1,6-biphosphate aldolase A; 
GSD XIII = β-enolase. 
13 
Certain populations have common AGL mutations as a result of a founder effect. In GSDIII 
patients from the Faroe Islands c.1222C>T is present (Santer et al 2001), and c.4455delT in 
North African Jewish patients (Parvari et al 1997). Except for the founder mutations and some 
other common mutations, most mutations are unique. Missense and splice site mutations, small 
deletions and insertions, and large intragenic deletions and insertions have been described, 
many of which produce truncated proteins. The c.4455delT mutation in the North African 
Jewish community generates a truncated protein that is about 97% of its length. This proves 
that the carboxy terminus, downstream of the glycogen binding site, is essential for normal 
enzyme function (Parvari et al 1997; Dagli et al 2010). Individuals with GSDIIIb have 
mutations in exon 3 of one of their AGL alleles. The nonsense mutation p.Gln6X and the 
frameshift deletion c.17_18delAG both generate truncated proteins with few amino acids. It is 
thought that alternative exon or translation initiation in muscle isoforms does not require exon 
3, thus leading to normal enzyme activity in the muscles of persons with GSDIIIb who have an 
exon 3 deletion (Shen et al 1996, Elpeleg 1999; Dagli et al 2010). 
Clinical Findings 
In the neonatal period and in infancy the main features of GSDIII are hepatomegaly, 
hyperketotic-hypoglycaemic episodes after fasting, and hyperlipidaemia. The aspartate 
aminotransferase (ASAT) and alanine aminotransferase (ALAT) levels are elevated during 
childhood, while the fasting lactate and uric acid levels are normal. Untreated neonates and 
children are bound to have developmental delay, growth retardation and delayed puberty 
(Laforêt et al 2012). Hepatomegaly is a hallmark feature at the first presentation, but during 
puberty the size of the liver usually returns to normal, possibly due to progressing fibrosis. 
Despite this fact, liver complications are still frequent, and the incidence is expected to increase 
with age (Wolfsdorf and Weinstein 2003). Pathologic examination of liver biopsy samples in 
adults show signs of (periportal) hepatic fibrosis, and hepatic adenomas are seen in 10-25% of 
the patients (Labrune et al 1997). Severe cases of GSDIII patients who develop liver cirrhosis 
and related complications such as ascites, oesophageal varices, and even hepatocellular 
carcinoma have been described as well (Haagsma et al 1997; Lee et al 1997; Okuda et al 1998; 
Demo et al 2007). 
GSDIIIa-related myopathy may present in childhood but usually is not clinically 
evident until patients reach their third decade. GSDIIIa-related myopathy presents as a slowly 
progressive muscle weakness in the proximal muscles of the shoulder and hip. In some patients 
there may be clinical muscle weakness of the small distal muscle-groups associated by the 
development of peripheral neuropathy (Slonim et al 1984; Wary et al 2010). Cardiomyopathy 
is a frequent complication in GSDIIIa since limit dextrin can also be stored in myocardial cells 
and between bundles of myofilaments. This situation causes a form of cardiomyopathy that 
echocardiographically resembles idiopathic hypertrophic cardiomyopathy, but shows a 
different response to exercise testing, 24-hour electrocardiographic monitoring and thallium-
201 myocardial scintigraphy (Lee et al 1997). The clinical significance and long-term 
consequences of GSDIIIa related cardiomyopathy are unclear due to a lack of data and 
experience. Recently, the beneficial effects of a high protein diet, in which around 20-30% of 
total energy is derived from protein, in GSDIIIa-related cardiomyopathy have been described. 
In three separate case-reports, three severely symptomatic patients with GSDIIIa-related 
hypertrophic cardiomyopathy improved both clinically objectively on a high protein diet with 
a limited supply of carbohydrates (Dagli et al 2009; Valayannopoulos et al 2011; Sentner et al 
2012). 
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Adequate dietary treatment of GSDIII can improve metabolic control, meaning that 
hypoglycaemic episodes are prevented, and cholesterol and triglyceride concentrations are 
decreased (Gremse et al 1990; Weinstein and Wolfsdorf 2002). The aim of dietary management 
in GSDIII patients should be to maintain normoglycaemia by dividing the carbohydrate intake 
throughout the day. This can be achieved by taking frequent meals and/or regular doses of 
uncooked cornstarch. Uncooked cornstarch has a compact chemical structure consisting of 
glucose molecules, which can be slowly degraded, providing a stable glucose supply. Extra 
protein supplementation is advised as protein may be used in gluconeogenesis in fasting 
conditions (Slonim et al 1984; Wary et al 2010). Also, several case-reports have demonstrated 
that the implementation of a protein-enriched diet has reduced, and even reversed hypertrophic 
cardiomyopathy in GSDIIIa patients (Dagli et al 2009; Sentner et al 2011; Valayannopoulos 
et al. 2011). During night-time the use of uncooked cornstarch in combination with protein-
enriched feeds can prevent nocturnal hypoglycaemic episodes and improve metabolic control. 
In GSDIII the intake of products containing galactose and fructose does not have to be 
restricted, as these short glucose polymers can be processed normally (Weinstein & Wolfsdorf 
2002). Severe hypoglycaemic episodes should be treated immediately on admission to the 
emergency room by intravenous infusion of 10% dextrose with 0,5 normal saline administered 
at 1,5 times the maintenance rate. Serum concentrations of glucose, electrolytes, and ketones 
should be monitored. Ketosis should be corrected, as it can induce vomiting and worsen the 
catabolic state (Dagli et al 2010).
Discussion 
In GSDIII patients the incidence of hypertrophic cardiomyopathy, skeletal myopathy, and 
hepatic complications are the main cause of morbidity and mortality (Weinstein & Wolfsdorf 
2002). The prognosis of every individual GSDIII patient varies, but in general the patients with 
GSDIIIb have a better prognosis compared to GSDIIIa patients, probably because in GSDIIIb 
the muscles are unaffected. Unfortunately, there is little information on the natural clinical 
course of GSDIII. Over time it became apparent that the development of liver fibrosis, cirrhosis 
and even hepatocellular carcinoma’s have a severe impact on the prognosis, as well as the 
progressive (cardio)myopathic and neuropathic complications (Slonim et al 1984; Ugawa et al 
1986; Hattori et al 1995; Lee et al 1997; Kiechl et al 1999; Demo et al 2007). GSDIII is a very 
rare condition, with an estimated prevalence in Europe of 1:80,000, and because of this each 
academic metabolic centre does not have enough patients to investigate the natural course. 
Therefore, the current state of knowledge is based on single centre experiences in small 
populations, and most treatment regimens are based on ‘best practice’. Even in the light of 
these findings, life expectancy in GSDIII has improved considerably over the past decades.
15 
Outline of this thesis 
The following research questions have been addressed: 
• Chapter 2: Is the DGGE method reliable for AGL mutation analysis? Are there (novel)
genotype-phenotype relationships?
• Chapter 3: What is the natural history of GSDIII, in terms of diagnosis, management,
clinical course and outcome?
• Chapter 4: What is the incidence and clinical course of hyperlipidaemia in GSDIII
patients?
• Chapter 5: Can cardiac hypertrophy and severe heart failure be reversed in an adult
GSD IIIa patient by low-calorie high-protein adjustments?
• Chapter 6: What are differences of muscle ultrasound density and muscle force between
patients with GSDI and GSDIII, and how does myopathy progress these patients?
Finally, in chapter 7 a summary along with a discussion and future perspectives are presented. 
Chapter 1 is partially adopted from: Dagli A, Sentner CP, Weinstein DA. Glycogen Storage 
Disease Type III. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, 
Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. 
Seattle (WA): University of Washington, Seattle; 1993-2017. 2010 Mar 9 [updated 2016 Dec 
29]. 
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The following research questions have been addressed: 
• Chapter 2: Is the DGGE method reliable for AGL mutation analysis? Are there (novel)
genotype-phenotype relationships?
• Chapter 3: What is the natural history of GSDIII, in terms of diagnosis, management,
clinical course and outcome?
• Chapter 4: What is the incidence and clinical course of hyperlipidaemia in GSDIII
patients?
• Chapter 5: Can cardiac hypertrophy and severe heart failure be reversed in an adult
GSD IIIa patient by low-calorie high-protein adjustments?
• Chapter 6: What are differences of muscle ultrasound density and muscle force between
patients with GSDI and GSDIII, and how does myopathy progress these patients?
Finally, in chapter 7 a summary along with a discussion and future perspectives are presented. 
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Glycogen Storage Disease type III (GSD III) is an autosomal recessive disorder in which a 
mutation in the AGL gene causes deficiency of the glycogen debranching enzyme. In childhood 
it is characterized by hepatomegaly, keto-hypoglycaemic episodes after short periods of 
fasting, and hyperlipidaemia. In adulthood myopathy, cardiomyopathy and liver cirrhosis are 
the main complications. To determine the genotype of the GSD III patients (n=14) diagnosed 
and treated in our centre, mutation analysis was performed by either denaturing gradient gel 
electrophoresis or full gene sequencing. We developed, validated and applied both methods, 
and in all patients a mutation was identified on both alleles. Five novel pathogenic mutations 
were identified in seven patients, including four missense mutations (c.643G>A, p.Asp215Asn; 
c.655A>G, p.Asn219Asp; c.1027C>T, p.Arg343Trp; c.1877A>G, p.His626Arg), and one
frameshift mutation (c.3911delA, p.Asn1304fs). The c.643G>A, p.Asp215Asn mutation is
related with type IIIa, as this mutation was found homozygously in two patients. In addition to
five novel mutations, we present new genotype-phenotype relationships for c.2039G>A,
p.Trp680X; c.753_756delCAGA, p.Asp251fs; and the intron 32 c.4260-12A>G splice site
mutation. The p.Trp680X mutation was found homozygously in four patients, presenting a mild
IIIa phenotype with mild skeletal myopathy, elevated CK values, and no cardiomyopathy. The
p.Asp251fs mutation was found homozygously in one patient presenting with a severe IIIa
phenotype, with skeletal myopathy, and severe symptomatic cardiomyopathy. The c.4260-
12A>G mutation was found heterozygously, together with the p.Arg343Trp mutation in a
severe IIIb patient who developed liver cirrhosis and hepatocellular carcinoma, necessitating










Glycogen storage disease type III (GSDIII; OMIM no. 233400) is an autosomal recessive 
disorder in which mutations in the AGL gene cause deficiency of amylo-1,6-glucosidase, 1,4α-
D-glucan 4-α-glycosyltransferase, also known as the glycogen debranching enzyme (GDE; EC 
no. 3.2.1.33 and  2.4.1.25). GDE catalyses the last step in the conversion of glycogen to 
glucose, and GDE deficiency thus causes storage of an intermediate form of glycogen called 
limit dextrin (LD) (Smit et al 2006). In the IIIa subtype, muscle and liver tissue are deficient in 
GDE, and this affects 85% of GSDIII patients. Approximately 15% of the patients have type 
IIIb, in which only the liver is deficient in GDE (Shen et al 1996). In the neonatal period and 
in infancy, the main features are hepatomegaly with elevated aspartate transaminase (ASAT) 
and alanine transferase (ALAT) values, keto-hypoglycemic episodes after relatively short 
periods of fasting, and hyperlipidaemia. Untreated neonates and children have developmental 
delay, growth retardation, and delayed puberty. In puberty and early adulthood, myopathy 
becomes the predominant feature of GSDIII; the disease presents as a slowly progressive 
muscle weakness in which the proximal muscles of the shoulder and hip joints are affected. 
Clinical muscle weakness in the upper and the lower limb muscles can develop in later 
adulthood, which may be worsened by the development of peripheral neuropathy (Hobson-
Webb et al 2010; Wolfsdorf & Weinstein 2003). LD can also be stored in heart muscle, which 
causes a form of cardiomyopathy that resembles idiopathic hypertrophic cardiomyopathy on 
an echocardiogram (Lee et al 1997; Akazawa et al 1997). 
GDE is composed of 1532 amino acid residues, and has two catalytic centres (Bao et al 
1996; Lui et al 1991). Before GDE starts to act, a phosphorylase enzyme separates four glucose 
molecules from the glycogen molecule to form LD (Newgard et al 1989). Then the first 
catalytic centre of GDE, 1,4-glucan-4-D-glucosyltransferase, transports the outer three glucose 
molecules of LD to another chain. The second catalytic centre, amylo-1,6-glucosidase, then 
releases the last glucose molecule (Ding et al 1990). GSDIII can be diagnosed biochemically 
by measuring GDE activity in skin fibroblasts and/or leucocytes. GDE activity and LD content 
can also be measured in liver- and/or muscle biopsies (Wolfsdorf and Weinstein 2003). LD 
content can be measured in erythrocytes. 
The AGL gene is located on chromosome 1p22, and contains 35 exons covering 85 kb 
of DNA (Yang-Feng et al 1992). The full cDNA is 7 kb with a 4596 bp coding region. A total 
of six mRNA isoforms are created by alternative splicing. Isoform 1 is the major isoform and 
widely expressed, including in liver and muscle tissue (Bao et al 1996). Isoforms 2, 3, and 4 
are present in muscle and cardiac muscle and are formed by alternative splicing or because of 
the difference in transcription start points. Isoform 1 contains exons 1 and 3. Isoforms 2, 3, and 
4 start with exon 2. Isoforms 1 through 4 all contain exon 3, which includes the normal 
initiation codon for protein translation. Exons 4 through to 35 are present in all isoforms (Bao 
et al 1996; Bao et al 1997). The glycogen binding domain is encoded by exons 31-34. The 
1,4α-D-glucan 4-α-glycosyltransferase catalytic site is encoded by exons 6, 13, 14, and 15. The 
amylo-1,6-glucosidase catalytic site is encoded by exons 26 and 27 (Shen et al 2002). 
Molecular analyses of GSDIII patients have been performed in several ethnic 
populations and over 100 different AGL mutations have been described (Goldstein et al 2010), 
but new mutations are still being reported (http://www.hgmd.org). No clear genotype-
phenotype relationship has been established so far, although there is a relation between 
mutations in exon 3 and the IIIb subtype (Shen et al 1996; Shen et al 2002). It is unclear, 
however, what mechanism enables patients with mutations in exon 3 to retain GDE activity in 
muscle tissue. A possible explanation was proposed by Goldstein et al (2010) in which the 
exon 3 mutation is bypassed using a downstream start codon, thus creating an isoform without 
the exon 3 mutations. 
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Summary 
Glycogen Storage Disease type III (GSD III) is an autosomal recessive disorder in which a 
mutation in the AGL gene causes deficiency of the glycogen debranching enzyme. In childhood 
it is characterized by hepatomegaly, keto-hypoglycaemic episodes after short periods of 
fasting, and hyperlipidaemia. In adulthood myopathy, cardiomyopathy and liver cirrhosis are 
the main complications. To determine the genotype of the GSD III patients (n=14) diagnosed 
and treated in our centre, mutation analysis was performed by either denaturing gradient gel 
electrophoresis or full gene sequencing. We developed, validated and applied both methods, 
and in all patients a mutation was identified on both alleles. Five novel pathogenic mutations 
were identified in seven patients, including four missense mutations (c.643G>A, p.Asp215Asn; 
c.655A>G, p.Asn219Asp; c.1027C>T, p.Arg343Trp; c.1877A>G, p.His626Arg), and one
frameshift mutation (c.3911delA, p.Asn1304fs). The c.643G>A, p.Asp215Asn mutation is
related with type IIIa, as this mutation was found homozygously in two patients. In addition to
five novel mutations, we present new genotype-phenotype relationships for c.2039G>A,
p.Trp680X; c.753_756delCAGA, p.Asp251fs; and the intron 32 c.4260-12A>G splice site
mutation. The p.Trp680X mutation was found homozygously in four patients, presenting a mild
IIIa phenotype with mild skeletal myopathy, elevated CK values, and no cardiomyopathy. The
p.Asp251fs mutation was found homozygously in one patient presenting with a severe IIIa
phenotype, with skeletal myopathy, and severe symptomatic cardiomyopathy. The c.4260-
12A>G mutation was found heterozygously, together with the p.Arg343Trp mutation in a
severe IIIb patient who developed liver cirrhosis and hepatocellular carcinoma, necessitating
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of DNA (Yang-Feng et al 1992). The full cDNA is 7 kb with a 4596 bp coding region. A total 
of six mRNA isoforms are created by alternative splicing. Isoform 1 is the major isoform and 
widely expressed, including in liver and muscle tissue (Bao et al 1996). Isoforms 2, 3, and 4 
are present in muscle and cardiac muscle and are formed by alternative splicing or because of 
the difference in transcription start points. Isoform 1 contains exons 1 and 3. Isoforms 2, 3, and 
4 start with exon 2. Isoforms 1 through 4 all contain exon 3, which includes the normal 
initiation codon for protein translation. Exons 4 through to 35 are present in all isoforms (Bao 
et al 1996; Bao et al 1997). The glycogen binding domain is encoded by exons 31-34. The 
1,4α-D-glucan 4-α-glycosyltransferase catalytic site is encoded by exons 6, 13, 14, and 15. The 
amylo-1,6-glucosidase catalytic site is encoded by exons 26 and 27 (Shen et al 2002). 
Molecular analyses of GSDIII patients have been performed in several ethnic 
populations and over 100 different AGL mutations have been described (Goldstein et al 2010), 
but new mutations are still being reported (http://www.hgmd.org). No clear genotype-
phenotype relationship has been established so far, although there is a relation between 
mutations in exon 3 and the IIIb subtype (Shen et al 1996; Shen et al 2002). It is unclear, 
however, what mechanism enables patients with mutations in exon 3 to retain GDE activity in 
muscle tissue. A possible explanation was proposed by Goldstein et al (2010) in which the 
exon 3 mutation is bypassed using a downstream start codon, thus creating an isoform without 
the exon 3 mutations. 
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To determine the genotype of the GSDIII patients diagnosed and treated in our centre (n=14), 
the University Medical Centre Groningen (UMCG), the Netherlands, we performed mutation 
analysis by one of two methods. Denaturing gradient gel electrophoresis (DGGE) was applied 
on eight patients, and full gene sequencing was applied on six patients. We developed, 
validated, and applied both methods. Here we describe five novel mutations found in seven 
patients and their phenotypes, and evaluate the phenotype-genotype relationships in patients 
with previously described mutations. 
Materials and Methods 
Patients – For this study we analysed 14 patients diagnosed with GSDIII (seven females and 
seven males). They were diagnosed enzymatically by measuring GDE activity in leukocytes, 
fibroblasts, and/or liver tissue, and/or muscle tissue. All the patients were diagnosed and are 
being treated in the UMCG. Their clinical data was collected. 
Mutation analysis by DGGE – Genomic DNA was isolated from EDTA blood (Miller et al 
1988). Primers were designed on the GenBank genomic reference sequence (NW_012865) to 
include at least 40 bp of intronic sequence on the front end of every exon and at least 20 bp at 
the back end. Analysis with NGRL Manchester’s SNP database 
(http://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck.htm) confirmed that no known single 
nucleotide polymorphisms were situated under the primers. The primer specificity was checked 
and verified in complete genomic sequences with NCBI’s ePCR 
(http://www.ncbi.nlm.nih.gov/projects/e-pcr). We developed fifty primer sets to analyze 30 of 
the 33 coding exons by DGGE (primer sequences available upon request). The three remaining 
exons were sequenced directly, as designing DGGE primers with an appropriate melting curve 
was not possible. Per amplicon the amplification mix consisted of 1.0 µl genomic DNA (40 
ng/µl), 10 µl Amplitaq Gold ® Fast PCR Master Mix (Applied Biosystems, California, USA), 
3.0 µl primer (3 pmol/µl), and 6.0 µl milliQ water, the reaction volume per sample was 20.0 
µl. The samples were amplified by PCR in 96-well plates on a 96 well Gene Amp® 9700 PCR 
system (Applied Biosystems, California, USA). The PCR program used was: 3 minutes at 
96°C, 45 cycles of 1 minute at 96°C, 1 minute annealing at multiple temperatures, 1 minute 
elongation at 72°C, with a final extension step at 72°C lasting 5 minutes. The annealing 
temperatures were 5 cycles at 60°C, 5 cycles at 56°C, 5 cycles at 52°C and 30 cycles at 50°C. 
The PCR products were analyzed by DGGE (Hayes et al 1999). Amplicons showing an 
aberrant banding pattern were sequenced on an ABI 3730 automated sequencer (Applied 
Biosystems, California, USA) using specific primers. DNA samples from 38 GSD III patients 
with 34 known mutations were used to validate the DGGE system – and all mutations were 
detected in our system. 
Sequence analysis – We designed 33 primer sets according to the criteria used in conformation 
sensitive capillary electrophoresis (CSCE, table 1) and applied them for sequencing all coding 
exons of the gene including flanking intronic sequences. Per sample the amplification mix 
consisted of 2 µl genomic DNA, 5 µl Amplitaq Gold® Fast PCR Master Mix (Applied 
Biosystems, California, USA), and 3.0 µl primer (150 fmol/µl). The reaction volume per 
sample was 10 µl, the samples were amplified by PCR in 384-well plates on a Veriti 384-well 
thermal cycler (Applied Biosystems, California, USA). The PCR program was: 3 minutes at 
94°C, 35 cycles of 1 minute at 94°C, 1 minute annealing at 60°C, 1 minute at 72°C, and a final 
extension step at 72°C lasting 7 minutes, after which the samples were cooled down to 20°C. 
5 µl of the PCR products were loaded with 5 µl loading buffer and run on a 2% agarose gel 








remaining PCR products were purified with ExoSAP-IT (Amersham Pharmacia Biotech, 
Biscataway, NY, USA) and subjected to direct sequencing on an ABI 3730 automated 
sequencer (Applied Biosystems, California, USA) using specific primers. 
 
Table 1. Sequences of the primer set designed according to the criteria of primer design used in conformation 
sensitive capillary electrophoresis (CSCE). Primer and amplicon criteria: Optimal primer length 20bp (minimum 
18bp; maximum 27bp), optimal annealing temperature 58◦C (minimum 52◦C; maximum 64◦C), optimal GC% 55 
(maximum 70), optimal amplicon size 400bp (minimum 200bp; maximum 464bp), maximal amplicon GC% 73. 
A PT1 tail was added to every forward primer sequence (‘5-‘3; TGTAAAACGACGGCCAGT), and a PT2 tail 
was added to every reverse primer sequence (‘5-‘3; CAGGAAACAGCTATGACC). 
 
Amplicon Forward Primer Sequence 5’-3’ Reverse Primer Sequence 5’-3’ Size bp 
3 CGAACATGTAAGTGCCGCTGTCA AGAACACAGCACCATCTTTGCACAA 380 
4 GTAGTGCCAAAACAGCATTAGGTTTGC GCACTGCCATGGTTCATACAGTAACAT 457 
5 TTCCATTAAGTTTTGTTGCAAC CTGCAATGAGAGAATGGACTAATACAC 435 
6 TGAACCCAAGTGTTTGACCTCTTTTCC CCTTTCTCTTATTTGTGTGTATATGTG 432 
7 AACTTTTCCTGTAACAGTATCATCG AATACAGGTTCTAAGTAATTTTCAACC 429 
8 GCACTTTGGCGTTTCTCCTGTGA GACGTTACCCAAAAGAGAGTTTTCCCT 460 
9 GGGAGGAGGTAGGAGGATAC CACATATAGAAACATGGCCCACACACA 456 
10 CTGTGTGTGGGCCATGTTTCTATATGT TTCCCAAAAGGCAATTAACTGCCTGAA 409 
11 CTGCATTTCTCCATCTGCTCTAGCAA ATTTAAGAAATGTACTGAACTCACATG 440 
12 CATCCTGCTAGATTTACTCAAAAAGCC ACCAATAGACTAATGGGGAAGAAAATC 432 
13 TTAAAAACCAGTGTTTCCTTGAAG AATGCTTGTGTCCAACTAGC 381 
14 TATGTCAAATCATGCCTCCTTTTGTC GAAATGAGGTATCTTACCCCAAAGTAG 428 
15 CCATTTCTCCAGTTAAGTTATGGG TGGGTATGATTGTGACCAAGTGTCAGA 445 
16 GGTCACAATCATACCCATATACTTC AAACCACTGAAATCTGGACAAAGG 442 
17 CTATGGCATGTTGTGCTAGTGGAAGT TCCACATACACCTGAGAAGCAGAAAGA 433 
18 AGGAGCTTGGAGCCAAGGGTTT CCATCATACCTGGCCAAGTTACCAAA 447 
19 GATTTGAAACCACTTTAGCCTTCC TGTGGCAACTCCAGCTTGTTTAAC 340 
20 TGGGACTCTCATCTTACTACTGTG GCATGTGGATCAAGACTAACTCTG 340 
22 TTGAAAACTTGTCTCCAGGAAGTG TGGACCGTACTTTGAGTAGCAAGGAT 402 
22 GAATGCTGAGTTCCTAAAACATACAC TGCAACCCAAGTAGGCATACTCTGA 366 
23 TTGTGGACTGGGTAGCCCTTGT GAAGGAAGGAGGAAAATGGTTCAGGTT 397 
24 CCTCCTTCCTTCATCATCTTTCAG CTATCCACCTACAAGCCTTTTCAG 413 
25 TGGGTGAAATGAAAGCAGTTTTG AAAATCTTGAGTAGCATTACAAGC 458 
26 ACCCCAGGTTTAGAGTAACTGTTC CTACCTAAAGAAAATACAGCTCCC 323 
27 CAAAAGTGACTGGTTTTTGTCTTC GGTGCCAAATCAATACTGACATTTG 440 
28 CTGGCCTCACCCCAATTCCTATTTC ATTATATCGTGAGGTTTGGCACAC 352 
29 CAAACTGAGCTTTAGAGTGGTTGTCCT AGATGAAGGGAAGAAGGCAGGGAAAT 398 
30 TTCATTACAATTGTTTACCGAATGCCC GGGTTTTCCGATATTAGCTGATAG 301 
31 CACATCTCAATTCAGACTGGCCACAT AACAAATGGGAATAAGGAACTAAGC 441 
32 GGCTTTCCTAACTTCTACGGCCAAAA AGATGGCATCTCCTTTTGTTGCCC 407 
33 TGCCGAGCTTATTCTGTAGAAGAC AGGCCACAGCCACTCCTAAAAAAG 333 
34 TCACCAAGGACCTGTAAGAATTTC CCTAGGGCATACAGAAATCAATTC 350 
35 CACTAGAAGGCAAAAATCACCAGGTCT AACTTGAGCCTGTGCATATAAGGCATT 294 
 
Analysis of the pathogenicity of novel mutations – The pathogenicity of novel mutations was 
assessed using six separate methods. 100 control chromosomes from mixed ethnicity were 
checked for the novel mutations. Conservation of the mutated nucleotide and amino acid was 
graded with Alamut Version 1.4 (©Interactive Biosoftware). The University of Harvard’s 
PolyPhen program (http://genetics.bwh.harvard.edu/pph/) predicted the impact of an amino 
acid substitution on the structure and function of a human protein. The SIFT program 
(http://blocks.fhcrc.org/sift/SIFT.html) predicted whether an amino acid substitution affects 
protein function based on sequence homology and the physical properties of amino acids. 
Finally, we assessed whether the mutation was located in an exon encoding the glycogen 
binding domain (exon 31-34), or encoding a catalytic site (exon 6, 14 16, 26-27), and measured 
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To determine the genotype of the GSDIII patients diagnosed and treated in our centre (n=14), 
the University Medical Centre Groningen (UMCG), the Netherlands, we performed mutation 
analysis by one of two methods. Denaturing gradient gel electrophoresis (DGGE) was applied 
on eight patients, and full gene sequencing was applied on six patients. We developed, 
validated, and applied both methods. Here we describe five novel mutations found in seven 
patients and their phenotypes, and evaluate the phenotype-genotype relationships in patients 
with previously described mutations. 
Materials and Methods 
Patients – For this study we analysed 14 patients diagnosed with GSDIII (seven females and 
seven males). They were diagnosed enzymatically by measuring GDE activity in leukocytes, 
fibroblasts, and/or liver tissue, and/or muscle tissue. All the patients were diagnosed and are 
being treated in the UMCG. Their clinical data was collected. 
Mutation analysis by DGGE – Genomic DNA was isolated from EDTA blood (Miller et al 
1988). Primers were designed on the GenBank genomic reference sequence (NW_012865) to 
include at least 40 bp of intronic sequence on the front end of every exon and at least 20 bp at 
the back end. Analysis with NGRL Manchester’s SNP database 
(http://ngrl.manchester.ac.uk/SNPCheckV2/snpcheck.htm) confirmed that no known single 
nucleotide polymorphisms were situated under the primers. The primer specificity was checked 
and verified in complete genomic sequences with NCBI’s ePCR 
(http://www.ncbi.nlm.nih.gov/projects/e-pcr). We developed fifty primer sets to analyze 30 of 
the 33 coding exons by DGGE (primer sequences available upon request). The three remaining 
exons were sequenced directly, as designing DGGE primers with an appropriate melting curve 
was not possible. Per amplicon the amplification mix consisted of 1.0 µl genomic DNA (40 
ng/µl), 10 µl Amplitaq Gold ® Fast PCR Master Mix (Applied Biosystems, California, USA), 
3.0 µl primer (3 pmol/µl), and 6.0 µl milliQ water, the reaction volume per sample was 20.0 
µl. The samples were amplified by PCR in 96-well plates on a 96 well Gene Amp® 9700 PCR 
system (Applied Biosystems, California, USA). The PCR program used was: 3 minutes at 
96°C, 45 cycles of 1 minute at 96°C, 1 minute annealing at multiple temperatures, 1 minute 
elongation at 72°C, with a final extension step at 72°C lasting 5 minutes. The annealing 
temperatures were 5 cycles at 60°C, 5 cycles at 56°C, 5 cycles at 52°C and 30 cycles at 50°C. 
The PCR products were analyzed by DGGE (Hayes et al 1999). Amplicons showing an 
aberrant banding pattern were sequenced on an ABI 3730 automated sequencer (Applied 
Biosystems, California, USA) using specific primers. DNA samples from 38 GSD III patients 
with 34 known mutations were used to validate the DGGE system – and all mutations were 
detected in our system. 
Sequence analysis – We designed 33 primer sets according to the criteria used in conformation 
sensitive capillary electrophoresis (CSCE, table 1) and applied them for sequencing all coding 
exons of the gene including flanking intronic sequences. Per sample the amplification mix 
consisted of 2 µl genomic DNA, 5 µl Amplitaq Gold® Fast PCR Master Mix (Applied 
Biosystems, California, USA), and 3.0 µl primer (150 fmol/µl). The reaction volume per 
sample was 10 µl, the samples were amplified by PCR in 384-well plates on a Veriti 384-well 
thermal cycler (Applied Biosystems, California, USA). The PCR program was: 3 minutes at 
94°C, 35 cycles of 1 minute at 94°C, 1 minute annealing at 60°C, 1 minute at 72°C, and a final 
extension step at 72°C lasting 7 minutes, after which the samples were cooled down to 20°C. 
5 µl of the PCR products were loaded with 5 µl loading buffer and run on a 2% agarose gel 








remaining PCR products were purified with ExoSAP-IT (Amersham Pharmacia Biotech, 
Biscataway, NY, USA) and subjected to direct sequencing on an ABI 3730 automated 
sequencer (Applied Biosystems, California, USA) using specific primers. 
 
Table 1. Sequences of the primer set designed according to the criteria of primer design used in conformation 
sensitive capillary electrophoresis (CSCE). Primer and amplicon criteria: Optimal primer length 20bp (minimum 
18bp; maximum 27bp), optimal annealing temperature 58◦C (minimum 52◦C; maximum 64◦C), optimal GC% 55 
(maximum 70), optimal amplicon size 400bp (minimum 200bp; maximum 464bp), maximal amplicon GC% 73. 
A PT1 tail was added to every forward primer sequence (‘5-‘3; TGTAAAACGACGGCCAGT), and a PT2 tail 
was added to every reverse primer sequence (‘5-‘3; CAGGAAACAGCTATGACC). 
 
Amplicon Forward Primer Sequence 5’-3’ Reverse Primer Sequence 5’-3’ Size bp 
3 CGAACATGTAAGTGCCGCTGTCA AGAACACAGCACCATCTTTGCACAA 380 
4 GTAGTGCCAAAACAGCATTAGGTTTGC GCACTGCCATGGTTCATACAGTAACAT 457 
5 TTCCATTAAGTTTTGTTGCAAC CTGCAATGAGAGAATGGACTAATACAC 435 
6 TGAACCCAAGTGTTTGACCTCTTTTCC CCTTTCTCTTATTTGTGTGTATATGTG 432 
7 AACTTTTCCTGTAACAGTATCATCG AATACAGGTTCTAAGTAATTTTCAACC 429 
8 GCACTTTGGCGTTTCTCCTGTGA GACGTTACCCAAAAGAGAGTTTTCCCT 460 
9 GGGAGGAGGTAGGAGGATAC CACATATAGAAACATGGCCCACACACA 456 
10 CTGTGTGTGGGCCATGTTTCTATATGT TTCCCAAAAGGCAATTAACTGCCTGAA 409 
11 CTGCATTTCTCCATCTGCTCTAGCAA ATTTAAGAAATGTACTGAACTCACATG 440 
12 CATCCTGCTAGATTTACTCAAAAAGCC ACCAATAGACTAATGGGGAAGAAAATC 432 
13 TTAAAAACCAGTGTTTCCTTGAAG AATGCTTGTGTCCAACTAGC 381 
14 TATGTCAAATCATGCCTCCTTTTGTC GAAATGAGGTATCTTACCCCAAAGTAG 428 
15 CCATTTCTCCAGTTAAGTTATGGG TGGGTATGATTGTGACCAAGTGTCAGA 445 
16 GGTCACAATCATACCCATATACTTC AAACCACTGAAATCTGGACAAAGG 442 
17 CTATGGCATGTTGTGCTAGTGGAAGT TCCACATACACCTGAGAAGCAGAAAGA 433 
18 AGGAGCTTGGAGCCAAGGGTTT CCATCATACCTGGCCAAGTTACCAAA 447 
19 GATTTGAAACCACTTTAGCCTTCC TGTGGCAACTCCAGCTTGTTTAAC 340 
20 TGGGACTCTCATCTTACTACTGTG GCATGTGGATCAAGACTAACTCTG 340 
22 TTGAAAACTTGTCTCCAGGAAGTG TGGACCGTACTTTGAGTAGCAAGGAT 402 
22 GAATGCTGAGTTCCTAAAACATACAC TGCAACCCAAGTAGGCATACTCTGA 366 
23 TTGTGGACTGGGTAGCCCTTGT GAAGGAAGGAGGAAAATGGTTCAGGTT 397 
24 CCTCCTTCCTTCATCATCTTTCAG CTATCCACCTACAAGCCTTTTCAG 413 
25 TGGGTGAAATGAAAGCAGTTTTG AAAATCTTGAGTAGCATTACAAGC 458 
26 ACCCCAGGTTTAGAGTAACTGTTC CTACCTAAAGAAAATACAGCTCCC 323 
27 CAAAAGTGACTGGTTTTTGTCTTC GGTGCCAAATCAATACTGACATTTG 440 
28 CTGGCCTCACCCCAATTCCTATTTC ATTATATCGTGAGGTTTGGCACAC 352 
29 CAAACTGAGCTTTAGAGTGGTTGTCCT AGATGAAGGGAAGAAGGCAGGGAAAT 398 
30 TTCATTACAATTGTTTACCGAATGCCC GGGTTTTCCGATATTAGCTGATAG 301 
31 CACATCTCAATTCAGACTGGCCACAT AACAAATGGGAATAAGGAACTAAGC 441 
32 GGCTTTCCTAACTTCTACGGCCAAAA AGATGGCATCTCCTTTTGTTGCCC 407 
33 TGCCGAGCTTATTCTGTAGAAGAC AGGCCACAGCCACTCCTAAAAAAG 333 
34 TCACCAAGGACCTGTAAGAATTTC CCTAGGGCATACAGAAATCAATTC 350 
35 CACTAGAAGGCAAAAATCACCAGGTCT AACTTGAGCCTGTGCATATAAGGCATT 294 
 
Analysis of the pathogenicity of novel mutations – The pathogenicity of novel mutations was 
assessed using six separate methods. 100 control chromosomes from mixed ethnicity were 
checked for the novel mutations. Conservation of the mutated nucleotide and amino acid was 
graded with Alamut Version 1.4 (©Interactive Biosoftware). The University of Harvard’s 
PolyPhen program (http://genetics.bwh.harvard.edu/pph/) predicted the impact of an amino 
acid substitution on the structure and function of a human protein. The SIFT program 
(http://blocks.fhcrc.org/sift/SIFT.html) predicted whether an amino acid substitution affects 
protein function based on sequence homology and the physical properties of amino acids. 
Finally, we assessed whether the mutation was located in an exon encoding the glycogen 
binding domain (exon 31-34), or encoding a catalytic site (exon 6, 14 16, 26-27), and measured 
















Patients – Of our 14 GSDIII patients, four were related to one other patient (two sisters, and 
two brothers), all other patients were unrelated. Patient 7 was born to consanguineous parents. 
Nine patients with type IIIa, two with type IIIb, and three patients were too young to be 
subtyped based on their clinical presentation. The clinical and biochemical characteristics of 
the patients are presented in table 2. 
 
 
Table 2. Demographic, clinical and biochemical characteristics of the analyzed GSD III patients. # M = Male, F 



















1 8 M Caribbean 0 Hepatomegaly None Proximal 
myopathy 
1083 
2 25 F Caribbean 0 Hepatomegaly None None 2232 
3 26 M Caribbean 0 Hepatomegaly Septal 
hypertrophy 
None 893 
4 40 F Caribbean 0 Hepatomegaly None None 3729 
5 15 F Mediterranean 0 Hepatomegaly None None 662 
6 20 F Mediterranean 0 Hepatomegaly None None 1342 









8 3 M Caucasian 1 Hepatomegaly None None 133 




10 30 M Caucasian 0 Hepatomegaly None None 68 
11 41 F Caucasian 0 Hepatomegaly None Exercise 
intolerance 
392 
12 41 F Caucasian 0 None, the 
patient is post-
OLT%, 





None None 70 
13 3 M Caucasian 0 Hepatomegaly None None 128 
14 1 M Caucasian 0 Hepatomegaly None None 466 
 
 
Results of mutation analysis – The patients were fully analyzed and we detected two mutations 
in each patient (table 3). Five novel mutations were identified in seven patients, including two 
sisters who were homozygous for c.643G>A, p.Asp215Asn, and two brothers who were 
homozygous for c.3911delA, p.Asn1304fs. The other three patients were compound 
heterozygous with a novel missense mutation and a previously reported pathogenic mutation: 
c.655A>G, p.Asn219Asp in combination with c.4529dupA, p.Tyr1510X; c.1027C>T, 
p.Arg343Trp in combination with the splice mutation c.4260-12A>G, and c.1877A>G, 





Table 3. Mutation analysis results in fourteen GSD III patients. 
Results of pathogenicity analysis – We consider the four new missense mutations to be 
pathogenic for several reasons. We did not detect the new mutations in 100 control 
chromosomes, and these mutations were not found in the NCBI SNP database. Highly 
conserved  amino  acids  were  mutated, and  all  mutations  were  predicted  to  affect protein  
function by the PolyPhen and SIFT programs. Additionally, three of the four new mutations 
(Asp215Asn; p.Asn219Asp; and p.His626Arg) were located in an exon encoding the 1,4α-D-
glucan 4-α-glycosyltransferase catalytic site of GDE (figure 1). This makes a pathogenic effect 
of these mutations on GDE function very probable (Cheng et al 2009). As the c.3911delA, 
p.Asn1304fs causes a frameshift with the new reading frame ending in a stop codon at position
10, this is considered to be a pathogenic mutation as well. Clinically, all the patients presented
with a GSDIII phenotype, and this was biochemically confirmed by enzymatic analysis that no
GDE activity was measured to be present.
Table 4. Evidence of the pathogenic effect of the novel missense mutations reported. 
Mutation Conservation 
of the amino 
acid
Occurrence 









High Absent Probably 
damaging 
Not tolerated Active site, exon 6 
c.655A>G,
p.Asn219Asp
High Absent Probably 
damaging 
Not tolerated Active site, exon 6 
c.1027C>T,
p.Arg343Trp
Moderate Absent Probably 
damaging 




High Absent Probably 
damaging 
























1 17 c.2039G>A p.Trp680X Nonsense 17 c.2039G>A p.Trp680X Nonsense DGGE 
2 17 c.2039G>A p.Trp680X Nonsense 17 c.2039G>A p.Trp680X Nonsense DGGE 
3 17 c.2039G>A p.Trp680X Nonsense 17 c.2039G>A p.Trp680X Nonsense DGGE 
4 17 c.2039G>A p.Trp680X Nonsense 17 c.2039G>A p.Trp680X Nonsense Sequencing 
5 6 c.643G>A p.Asp215Asn Missense 6 c.643G>A p.Asp215Asn Missense DGGE 
6 6 c.643G>A p.Asp215Asn Missense 6 c.643G>A p.Asp215Asn Missense DGGE 
7 7 c.753_756delCAGA p.Asp251fs Frameshift 7 c.753_756delCAGA p.Asp251fs Frameshift DGGE 
8 6 c.655A>G p.Asn219Asp Missense 35 c.4529dupA p.Tyr1510X Nonsense Sequencing 
9 35 c.4529dupA p.Tyr1510X Nonsense 35 c.4529dupA p.Tyr1510X Nonsense DGGE 
10 3 c.16C>T p.Gln6X Nonsense 3 c.16C>T p.Gln6X Nonsense DGGE 
11 11 c.1222C>T p.Arg408X Nonsense 15 c.1877A>G p.His626Arg Missense Sequencing 
12 9 c.1027C>T p.Arg343Trp Missense Intron 
32 
c.4260-12A>G Splice Sequencing 
13 30 c.3911delA p.Asn1304fs Frameshift 30 c.3911delA p.Asn1304fs Frameshift Sequencing 
14 30 c.3911delA p.Asn1304fs Frameshift 30 c.3911delA p.Asn1304fs Frameshift Sequencing 
14663 - Sentner_BNW.indd   26 18-05-17   09:44
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Results of mutation analysis – The patients were fully analyzed and we detected two mutations 
in each patient (table 3). Five novel mutations were identified in seven patients, including two 
sisters who were homozygous for c.643G>A, p.Asp215Asn, and two brothers who were 
homozygous for c.3911delA, p.Asn1304fs. The other three patients were compound 
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Table 3. Mutation analysis results in fourteen GSD III patients. 
Results of pathogenicity analysis – We consider the four new missense mutations to be 
pathogenic for several reasons. We did not detect the new mutations in 100 control 
chromosomes, and these mutations were not found in the NCBI SNP database. Highly 
conserved  amino  acids  were  mutated, and  all  mutations  were  predicted  to  affect protein  
function by the PolyPhen and SIFT programs. Additionally, three of the four new mutations 
(Asp215Asn; p.Asn219Asp; and p.His626Arg) were located in an exon encoding the 1,4α-D-
glucan 4-α-glycosyltransferase catalytic site of GDE (figure 1). This makes a pathogenic effect 
of these mutations on GDE function very probable (Cheng et al 2009). As the c.3911delA, 
p.Asn1304fs causes a frameshift with the new reading frame ending in a stop codon at position
10, this is considered to be a pathogenic mutation as well. Clinically, all the patients presented
with a GSDIII phenotype, and this was biochemically confirmed by enzymatic analysis that no
GDE activity was measured to be present.
Table 4. Evidence of the pathogenic effect of the novel missense mutations reported. 
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High Absent Probably 
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1 17 c.2039G>A p.Trp680X Nonsense 17 c.2039G>A p.Trp680X Nonsense DGGE 
2 17 c.2039G>A p.Trp680X Nonsense 17 c.2039G>A p.Trp680X Nonsense DGGE 
3 17 c.2039G>A p.Trp680X Nonsense 17 c.2039G>A p.Trp680X Nonsense DGGE 
4 17 c.2039G>A p.Trp680X Nonsense 17 c.2039G>A p.Trp680X Nonsense Sequencing 
5 6 c.643G>A p.Asp215Asn Missense 6 c.643G>A p.Asp215Asn Missense DGGE 
6 6 c.643G>A p.Asp215Asn Missense 6 c.643G>A p.Asp215Asn Missense DGGE 
7 7 c.753_756delCAGA p.Asp251fs Frameshift 7 c.753_756delCAGA p.Asp251fs Frameshift DGGE 
8 6 c.655A>G p.Asn219Asp Missense 35 c.4529dupA p.Tyr1510X Nonsense Sequencing 
9 35 c.4529dupA p.Tyr1510X Nonsense 35 c.4529dupA p.Tyr1510X Nonsense DGGE 
10 3 c.16C>T p.Gln6X Nonsense 3 c.16C>T p.Gln6X Nonsense DGGE 
11 11 c.1222C>T p.Arg408X Nonsense 15 c.1877A>G p.His626Arg Missense Sequencing 
12 9 c.1027C>T p.Arg343Trp Missense Intron 
32 
c.4260-12A>G Splice Sequencing 
13 30 c.3911delA p.Asn1304fs Frameshift 30 c.3911delA p.Asn1304fs Frameshift Sequencing 
14 30 c.3911delA p.Asn1304fs Frameshift 30 c.3911delA p.Asn1304fs Frameshift Sequencing 








Figure 1. The location of all found mutations in the gene, the catalytic sites of GDE are depicted as well; three 
of the four novel mutations (Asp215Asn; p.Asn219Asp; and p.His626Arg) were located in exons encoding the 












Here we describe five novel pathogenic mutations in the AGL gene, four of which are missense 
mutations, very likely causing GSDIII in seven patients. Missense mutations causing GSDIII 
are scarce, as truncating mutations compose the majority of the pathogenic mutations. 
However, pathogenic missense mutations have been described. Cheng et al showed that 
missense mutations located in the active sites produce a GSDIII phenotype in which there is 
total or partial abolishment of GDE activity depending on the location of the mutation (Cheng 
et al 2009). 
GSDIII is characterized by clinical and genotypical heterogeneity, and clear genotype-
phenotype correlations are rare. We therefore present the clinical characteristics of the patients 
with novel mutations, and discuss the correspondence between their clinical presentation and 
that described in the literature for the mutations that have been previously described. 
 
Genotype-phenotype analysis – Patients 1 to 4 all had type IIIa and were homozygous for 
p.Trp680X. The phenotype was similar in all four patients, with hepatomegaly, no or mild 
cardiac involvement, and mild skeletal myopathy with elevated CK values. This suggests a link 
between the p.Trp680X mutation and the type IIIa phenotype. The p.Trp680X mutation was 
described previously in a compound heterozygote patient, in whom it was linked to the IIIb 
phenotype (Shen et al 1996), which is in contrast to what we found in our patients. 
Interestingly, all our patients with the c.2039G>A, p.Trp680X mutation were from the same 
topographic region and ethnic origin, making a founder effect feasible, as seen for the 
c.1222C>T, p.Arg408X mutation on the Faroe Islands (Santer et al 2001). However, in order 
to prove this, haplotyping for these patients would be required, which we have not done in this 
study. 
Patient 5 (female, age 15 years) and patient 6 (female, age 20 years) were sisters whose 
parents are from the Mediterranean, who had type IIIa and were homozygous for the novel 
p.Asp215Asn mutation. Their phenotype is mild with hepatomegaly as the main finding, there 
is no myopathy or cardiomyopathy. In laboratory investigations ASAT, ALAT and CK values 
were elevated, but there was no hypoglycaemia or hyperlipidaemia. The mild phenotype was 
probably due to their young age and the good metabolic control of these patients. 
Patient 7 (female, age 32 years) had type IIIa and was found to be homozygous for 
p.Asp251fs. She had a severe phenotype, with hepatomegaly, and skeletal muscle involvement 
with severe exercise intolerance. There was also severe cardiac involvement with hypertrophy 
of the interventricular septum and left ventricle, necessitating pharmacological treatment and 
ICD placement. This mutation was previously described in a 3 year-old female, who was found 
to have hepatosplenomegaly and hypoglycaemia but no myopathy or cardiomyopathy 
(Lucchiari et al 2006). 
In patient 8 (male, age 3 years) the novel mutation p.Asn219Asp was found to be 
heterozygous. The other mutation p.Tyr1510X was previously reported and associated with a 
severe IIIa phenotype (Shen et al 1997). At first presentation (age 1.5 years), he had severe 
hepatomegaly extending 15 cm below the costal margin in the medioclavicular line, regular 
keto-hypoglycaemic episodes and hyperlipidaemia. These symptoms improved dramatically 
upon starting dietary treatment after diagnosis at the age of 1.5 years with frequent meals during 
the day and overnight gastric drip feeding. These findings are typical for GSDIII patients in 
this age group, and the normal CK value does not exclude future muscle involvement, making 
it hard to assess the subtype or to determine the phenotype that goes with this novel mutation. 
Furthermore, the latter proves difficult because the patient was found to have compound 
heterozygous mutations. Patient 9 (female, 30 years) had type IIIa was found to be homozygous 
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it hard to assess the subtype or to determine the phenotype that goes with this novel mutation. 
Furthermore, the latter proves difficult because the patient was found to have compound 
heterozygous mutations. Patient 9 (female, 30 years) had type IIIa was found to be homozygous 








for p.Tyr1510X and had a severe GSDIIIa phenotype. She had a severe phenotype including 
distal myopathy and severe exercise intolerance with elevated CK (2257 U/L). Despite the 
absence of hepatomegaly, transaminases remained elevated (ASAT 237 U/L, ALAT 175 U/L). 
This is in concordance with a suggestion made by Shen et al that this mutation is associated 
with a severe GSDIIIa phenotype (Shen et al 1997). 
Patient 10 (male, 30 years) had type IIIb and was homozygous for p.Gln6X. His current 
phenotype is mild, with hepatomegaly, normal CK values and no cardiac- or skeletal-muscle 
involvement. This mutation was previously described and is strongly linked with the GSD IIIb 
phenotype, as are other mutations in exon 3 (Shen et al 1996; Shen et al 2002). Paradoxically, 
this patient first presented at the age of 2 years with proximal myopathy and severe hypotonia, 
but without cardiomyopathy or elevated CK values. His myopathy and hypotonia improved 
dramatically upon starting dietary treatment, and he has had no muscular symptoms since. 
Patient 11 (female, age 41 years) had type IIIa and was compound heterozygous for the 
novel p.His626Arg mutation. Her other mutation p.Arg408X was previously described (Santer 
et al 2001; Lam et al 2004) and associated with the GSD IIIa phenotype. This corresponds with 
her phenotype: hepatomegaly and elevated transaminases. She has no proximal or distal 
myopathy but she does suffer from exercise intolerance and has elevated CK values. 
Patient 12 (female, age 41 years) had type IIIb and was compound heterozygous for the 
novel p.Arg343Trp mutation and c.4260-12A>G in intron 32. c.4260-12A>G was previously 
described and associated with IIIb as well as IIIa (Okubo et al 1998; Shaiu et al 2000). Her 
phenotype was severe IIIb and a case report on her was published after she received an 
orthotopic liver transplantation after being diagnosed with liver cirrhosis (Haagsma et al 1997). 
Hepatocellular carcinoma was found upon pathological examination of the excised liver. She 
has never had any muscle involvement, and CK values have always been normal. 
Patients 13 (male, age 3 years) and 14 (male, age 1 years) were brothers and 
homozygous for the novel mutation c.3911delA, p.Asn1304fs in exon 30. Except for prominent 
hepatomegaly and the need for appropriate dietary requirements, both patients were generally 
well. There was no clinical muscle involvement, even though patient 14 had elevated CK-
values. As these are pediatric patients it is not yet possible to assess the subtype based on the 
clinical findings. 
 
Conclusions – We identified two separate mutations in each of our 14 GSDIII patients. Five 
were novel pathogenic mutations considered to be causal. As we also analyzed parts of the 
intron sequences (40 bp on the front end, and 20 bp at the back end of every exon), we assume 
that the chance that we missed other disease-causing mutations is slim. The novel c.643G>A, 
p.Asp215Asn mutation is related with type IIIa, as this mutation was found homozygously in 
two patients both clinically presenting as type IIIa. We also established new genotype-
phenotype relationships between c.2039G>A, p.Trp680X and type IIIa; c.753_756delCAGA, 
p.Asp251fs and type IIIa; and between the intron 32 c.4260-12A>G splice site mutation and 
type IIIb. The association between c.4529dupA, p.Tyr1510X and type IIIa complies with 
previous literature. However, as the GSD III subtype is not yet clear for every patient, it was 
not possible to establish a genotype-phenotype relationship for every novel mutation. There is 
still a large clinical and genotypical heterogeneity in GSD III, which makes establishing 
genotype-phenotype relationships for GSD III difficult. The fact that we found five new 
mutations in a relatively small number of GSD III patients further accentuates the need for 
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Glycogen storage disease type III (GSDIII) is a rare disorder of glycogenolysis due 
to AGL gene mutations, causing glycogen debranching enzyme deficiency and storage of 
limited dextrin. Patients with GSDIIIa show involvement of liver and cardiac/skeletal muscle, 
whereas GSDIIIb patients display only liver symptoms and signs. The International Study on 
Glycogen Storage Disease (ISGSDIII) is a descriptive retrospective, international, multi-centre 
cohort study of diagnosis, genotype, management, clinical course and outcome of 175 patients 
from 147 families (86 % GSDIIIa; 14 % GSDIIIb), with follow-up into adulthood in 91 
patients. In total 58 AGL mutations (non-missense mutations were overrepresented and 21 
novel mutations were observed) were identified in 76 families. GSDIII patients first presented 
before the age of 1.5 years, hepatomegaly was the most common presenting clinical sign. 
Dietary management was very diverse and included frequent meals, uncooked cornstarch and 
continuous gastric drip feeding. Chronic complications involved the liver (hepatic cirrhosis, 
adenoma(s), and/or hepatocellular carcinoma in 11 %), heart (cardiac involvement and 
cardiomyopathy, in 58 % and 15 %, respectively, generally presenting in early childhood), and 
muscle (pain in 34 %). Type 2 diabetes mellitus was diagnosed in eight out of 91 adult patients 
(9 %). In adult patients no significant correlation was detected between (non-) 
missense AGL genotypes and hepatic, cardiac or muscular complications. This study 
demonstrates heterogeneity in a large cohort of ageing GSDIII patients. An international GSD 
patient registry is warranted to prospectively define the clinical course, heterogeneity and the 






































Glycogen storage disease type III (GSDIII; OMIM #232400) is a rare inborn error of glycogen 
degradation with an incidence of 1:100,000 (Dagli et al 2010; Kishnani et al 2010; Laforêt et 
al 2012). GSDIII is caused by mutations in the AGL gene and the subsequent deficiency of the 
glycogen debranching enzyme (GDE; EC no. 3.2.1.33 and 2.4.1.25, UniProt P35573). GDE 
contains two catalytic centres that catalyse one of the last steps in the conversion of glycogen 
to glucose-1-phosphate. 
Patients with GSDIII present clinically with hepatomegaly, failure to thrive and fasting 
intolerance, biochemically associated with ketotic hypoglycaemia. Phenotypically, patients can 
be further classified into having either GSDIIIa (±85 %), with involvement of the liver, heart 
and skeletal muscle, or GSDIIIb (±15 %), in which only the liver is affected (Shen et al 1996; 
Laforêt et al 2012). Dietary management aims to maintain normoglycaemia and prevent 
hyperketonaemia by dividing sufficient carbohydrate intake throughout the day, and using 
additional protein as a substrate for gluconeogenesis (as recently reviewed by Derks & Smit 
2015). During long-term follow-up the clinical focus shifts to the prevention and management 
of progressive hepatic, cardiac and myopathic complications (Dagli et al 2009; Sentner et al 
2012; Verbeek et al 2015). 
Current knowledge on the clinical course and outcome has been based on case reports 
and small single centre cohort studies, of mainly young patients, on which the current 
management guidelines are based (Dagli et al 2010; Kishnani et al 2010). The International 
Study on GSDIII (ISGSDIII) is a descriptive, retrospective, international, multi-centre cohort 
study on the diagnosis, genotype, management, clinical course and outcome in 175 patients 




The Medical Ethical Committee of the University Medical Centre Groningen, the Netherlands 
approved the study protocol (ref.no. METc2008.035). Patients were included from 17 
metabolic centres in ten countries. Between 2007 and 2011 data on GSDIII patients were 
collected using a case record form (CRF) for every patient and anonymously archived in a 
database. The CRF was based on the European Study on GSDI (ESGSDI; Rake et al 2002), 
and modified for ISGSDIII by two authors (GPAS, CPS) (for the complete CRF, see 
Supplemental data 1). The CRFs were filled out either by the treating physician or by one single 
investigator (CPS). 
GSDIII patients were included when an enzyme assay and/or AGL molecular analysis 
had confirmed the diagnosis. GSDIIIa was defined as (a) deficient GDE activity in muscle or 
(b) clinical and/or biochemical signs of cardiac and/or skeletal muscular involvement. Based 
on the family history, individual patients could be categorized as proband, symptomatic sibling 
or neonatally screened patient due to an affected older sibling. To study the relationship 
between AGL genotypes and GSDIII phenotypes, statistical analyses were only performed in 
adult patients. Cardiac involvement was defined as the presence of abnormalities 
corresponding to cardiac hypertrophy in the electrocardiographic and/or echocardiographic 
investigations. Cardiomyopathy was defined as the presence of cardiac hypertrophy in 
combination with 1) (severe) exercise intolerance (and/or 2) the use of pharmacological 
treatment for (symptoms of) heart failure. 
AGL mutations were grouped according to the type of mutation, i.e. missense or non-
missense AGL genotypes. Non-missense mutations resulting in either frameshift or splicing 
modifications were assumed to be pathogenic. Pathogenicity of novel missense mutations was 
predicted by five methods: Alamut Version 2.2 (©Interactive Biosoftware), PolyPhen-2 
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(http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.bii.a-star.edu.sg/), whether the 
mutation was located in the catalytic site (exon 6, 13-15, 26-27) or an exon encoding the 
glycogen binding domain (exons 31-34), and the NHLBI Exome Sequencing Project (ESP) 
Exome Variant Server (http://evs.gs.washington.edu/EVS/). 
Data were processed with IBM® SPSS® Statistics Version 20 (SPSS Inc., Chicago, Il, 
USA). The results were expressed as median (range) for non-parametric data, and mean 
(standard deviation) for parametric data. Differences between normally distributed continuous 
data were analysed using the unpaired two-tailed T-test. Not normally distributed data were 
analysed using the Mann-Whitney-U or Kruskal-Wallis test. For dichotomous data, the 




Two hundred and twenty-eight patients with GSDIII were identified. Data from 53 patients 
were incomplete and not included in the analysis. Table 1 presents demographic and diagnostic 
information on 175 patients with GSDIII from 147 families, of whom 91 (52 %) had reached 
adulthood. 
 
Table 1 Distribution of observations between GSDIIIa and GSDIIIb patients. 
 
 GSDIIIa GSDIIIb Total 
Demographic information    
Male/Female (n (%)) 69 (46%) / 82 (54%) 13 (52%) / 11 (48%) 82 (47%) / 93 (53%) 
Age (yrs: median (range)) 20.6 (1–64.1) 16.4 (0.3–50.7) 19.3 (0.3–64.2) 
Follow-up (yrs: median (range))  17.4 (0.5–61.1) 14.1(0.2 – 48.7) 16.2 (0.2–61.2) 
Ethnicity (n) 
Asian 2 1 3 
Caucasian-Mediterranean 125 23 148 
African-Caribbean 7 0 7 
Mixed 17 0 17 
 
Clinical course and presentation until establishment of the diagnosis 
 
Pregnancy, birth, and presenting symptoms – Post-natal hypoglycaemia was documented for 
six term, normal birth-weight patients (3 %). In the 147 probands, the median age at the first 
clinical presentation in GSDIIIa and GSDIIIb was at 0.7 year (range: day 1–8.1 years) and 1.0 
year (range: day 1–6.0 years), respectively. Common presenting symptoms included 
hepatomegaly (98 %), hypoglycaemia (53 %), failure to thrive (49 %) and recurrent illness 
and/or infections (17 %). 
 
Mutation analysis – Figure 1 presents the 58 individual reported mutations, including 21 novel 
mutations, depicted per exon/intron. AGL gene mutation analysis was performed in 76 out of 
147 families, two causative mutations were identified in 72 families (95 %), in four families 
one allelic mutation was identified. The majority (50/58; 86 %) were non-missense mutations 
resulting in a truncated protein. Among the probands in whom both affected alleles were 
identified, 47 were found to be homozygotes, and 23 were compound heterozygotes. No 
statistically significant correlation was recognized between a (non-) missense AGL genotype 













Figure 1 AGL mutations in the ISGSDIII-cohort depicted per exon/intron. 
 
 
Clinical course after establishment of the diagnosis 
 
Figure 2 presents the age (median and range) of onset of clinical features and complications. 
 
Hepatic complications – The overall prevalence of severe hepatic complications (hepatic 
cirrhosis, adenomas and/or HCC) was 11 % (19 out of 175 patients; one GSDIIIb; 12 females). 
In 11 patients hepatic adenomas had been diagnosed (seven females), two of these patients 
were overweight at the time of diagnosis, and none of these patients used oral contraceptives. 
Alpha-fetoprotein levels were measured for eight patients, in none of these patients levels were 
over 40 ng/ml. In four patients with hepatic cirrhosis, orthotopic liver transplantation was 
performed at a median age of 32 years (15–35; three females; one GSDIIIb). In two of these 
patients (one GSDIIIb) hepatocellular carcinoma (HCC) was diagnosed postoperatively upon 
pathological examination. Three patients in total had been diagnosed with HCC, all of whom 
had progressed from hepatic fibrosis, to cirrhosis, and then HCC. 
 
Cardiac complications – Cardiac involvement was reported in 58 % (87/151) of the GSDIIIa 
patients. Electrocardiographic and/or echocardiographic signs of left ventricular hypertrophy 
were found in 61 GSDIIIa patients. The remaining 26 patients had other forms of cardiac 
hypertrophy (isolated septal, right ventricular or biventricular hypertrophy). Cardiomyopathy 
was  reported in 15 % (22/151) of all GSDIIIa  patients. There were no  laboratory parameters 
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(cholesterol, triglycerides, ASAT, ALAT, CK) significantly increased in GSDIIIa patients with 
or without cardiomyopathy. Heart transplantations had not been performed in this cohort. 
 
Neuromuscular complications – Muscular pain after minimal exercise was reported by 59 
patients (34 %). Three patients were wheelchair dependent due to skeletal muscle involvement 
(signs of permanent muscle weakness with atrophy). Electromyography (EMG) data were 
available from 33 patients and mainly showed myopathic changes, such as fibrillations and 
positive sharp waves. In 124 GSDIIIa patients (81 %) CK concentrations were elevated at some 
point at a median age of 10 years (0.3 – 56.1). Cardiomyopathy was associated with a 
significantly higher prevalence of distal myopathy (Fisher’s exact p = 0.034) and muscular pain 
after minimal exercise (Fisher’s exact p = 0.030). 
 
Growth and development – Adult height was reached at a median age of 19 years (15–23) 
(Table 2). There was no significant difference between GSDIIIa and GSDIIIb patients 
(p = 0.18). Of the patients who had reached adult height 24 % (21/86) had a BMI over 25 kg/m2 
at the latest follow-up, i.e. overweight according to WHO criteria. Pubertal development was 
delayed in 36 patients, and there was no significant difference between the subtypes (p = 0.72). 
Furthermore, no significant difference was found in adult height in SDS between the patients 
who had delayed compared to normal pubertal development (p = 0.15). 
 
Table 2 Height in SDS (compared to age-, gender- and ethnically corrected reference values) at latest follow-up 
in all patients. 
 
Age group (yrs) N Median Height SDS (range) N (%) < -2.0 SDS 
0.0 – 2.0 10 -0.16 (-2.45 – 0.60) 1 (10) 
2.0 – 5.0 20 -1.19 (-2.96 – 1.56) 2 (10) 
5.0 – 10.0 27 -0.71 (-2.86 – 1.65) 5 (19) 
10.0 – 15.0 24 -0.56 (-1.99 – 1.06) - 
15.0 – 20.0 26  0.26 (-1.81 – 2.50) - 
> 20.0 61  0.13 (-2.86 – 2.46) 2 (3) 
Total 168 -0.31 (-2.96 – 2.50) 10 (6) 
 
Bones – Bone fractures were reported in 16 patients with median age 7.5 years (range 1-18). 
According to WHO criteria (T-scores), 14 GSDIIIa patients had normal bone mineral density 
(BMD), 12 patients had osteopenia and six patients had osteoporosis (all GSDIIIa patients). 
Significantly increased CK (Kruskal-Wallis p = 0.004) and ALAT (Kruskal-Wallis p = 0.027) 
values were observed in the osteoporosis group when compared with the normal BMD-group. 
Hyperlipidaemia – Serum cholesterol and triglyceride concentrations were measured at the 
latest follow–up for 154 and 156 GSDIII patients, respectively. Cholesterol concentrations 
were consistently elevated (>5.17 mmol/L) in 34 % of the evaluated patients across different 
age groups. Triglyceride concentrations were mainly elevated (>1.69 mmol/L) in early 
childhood (in 23/29 79 %) patients up to 5 years. Between the age of 5 and 15 years this 
incidence decreased to 72 % (31/43), and after the age of 15 years stabilized to 40 % (34/84). 
Complications due to hyperlipidaemia, such as atherosclerosis or pancreatitis, were not 
reported in this population. 
 
Endocrinologic complications – Type 2 diabetes mellitus (DM2) was diagnosed in eight out of 
91 adult patients (9 %; all GSDIIIa), at median age of 38 years (32–44). Three patients were 
treated with insulin, and five with dietary adjustments. Four of these patients were overweight 
(BMI >25 kg/m2). HCC was not reported in patients with type 2 diabetes mellitus. Hirsutism 
14663 - Sentner_BNW.indd   40 18-05-17   09:44

















(cholesterol, triglycerides, ASAT, ALAT, CK) significantly increased in GSDIIIa patients with 
or without cardiomyopathy. Heart transplantations had not been performed in this cohort. 
 
Neuromuscular complications – Muscular pain after minimal exercise was reported by 59 
patients (34 %). Three patients were wheelchair dependent due to skeletal muscle involvement 
(signs of permanent muscle weakness with atrophy). Electromyography (EMG) data were 
available from 33 patients and mainly showed myopathic changes, such as fibrillations and 
positive sharp waves. In 124 GSDIIIa patients (81 %) CK concentrations were elevated at some 
point at a median age of 10 years (0.3 – 56.1). Cardiomyopathy was associated with a 
significantly higher prevalence of distal myopathy (Fisher’s exact p = 0.034) and muscular pain 
after minimal exercise (Fisher’s exact p = 0.030). 
 
Growth and development – Adult height was reached at a median age of 19 years (15–23) 
(Table 2). There was no significant difference between GSDIIIa and GSDIIIb patients 
(p = 0.18). Of the patients who had reached adult height 24 % (21/86) had a BMI over 25 kg/m2 
at the latest follow-up, i.e. overweight according to WHO criteria. Pubertal development was 
delayed in 36 patients, and there was no significant difference between the subtypes (p = 0.72). 
Furthermore, no significant difference was found in adult height in SDS between the patients 
who had delayed compared to normal pubertal development (p = 0.15). 
 
Table 2 Height in SDS (compared to age-, gender- and ethnically corrected reference values) at latest follow-up 
in all patients. 
 
Age group (yrs) N Median Height SDS (range) N (%) < -2.0 SDS 
0.0 – 2.0 10 -0.16 (-2.45 – 0.60) 1 (10) 
2.0 – 5.0 20 -1.19 (-2.96 – 1.56) 2 (10) 
5.0 – 10.0 27 -0.71 (-2.86 – 1.65) 5 (19) 
10.0 – 15.0 24 -0.56 (-1.99 – 1.06) - 
15.0 – 20.0 26  0.26 (-1.81 – 2.50) - 
> 20.0 61  0.13 (-2.86 – 2.46) 2 (3) 
Total 168 -0.31 (-2.96 – 2.50) 10 (6) 
 
Bones – Bone fractures were reported in 16 patients with median age 7.5 years (range 1-18). 
According to WHO criteria (T-scores), 14 GSDIIIa patients had normal bone mineral density 
(BMD), 12 patients had osteopenia and six patients had osteoporosis (all GSDIIIa patients). 
Significantly increased CK (Kruskal-Wallis p = 0.004) and ALAT (Kruskal-Wallis p = 0.027) 
values were observed in the osteoporosis group when compared with the normal BMD-group. 
Hyperlipidaemia – Serum cholesterol and triglyceride concentrations were measured at the 
latest follow–up for 154 and 156 GSDIII patients, respectively. Cholesterol concentrations 
were consistently elevated (>5.17 mmol/L) in 34 % of the evaluated patients across different 
age groups. Triglyceride concentrations were mainly elevated (>1.69 mmol/L) in early 
childhood (in 23/29 79 %) patients up to 5 years. Between the age of 5 and 15 years this 
incidence decreased to 72 % (31/43), and after the age of 15 years stabilized to 40 % (34/84). 
Complications due to hyperlipidaemia, such as atherosclerosis or pancreatitis, were not 
reported in this population. 
 
Endocrinologic complications – Type 2 diabetes mellitus (DM2) was diagnosed in eight out of 
91 adult patients (9 %; all GSDIIIa), at median age of 38 years (32–44). Three patients were 
treated with insulin, and five with dietary adjustments. Four of these patients were overweight 
(BMI >25 kg/m2). HCC was not reported in patients with type 2 diabetes mellitus. Hirsutism 








was described in one patient. Irregular menses or amenorrhea was described in 19 patients. 
Polycystic ovaries were diagnosed by ultrasound in five patients at a median age of 19 years 
(6–30). 
 
Mental and social development – Mental development was reported as normal in the majority 
of the patients, six patients displayed low or borderline intelligence (3 %) and one patient 
displayed severe developmental delay. Of the patients over 15 years of age (n = 101), 50 
patients (50 %) had normal employment and 23 patients (23 %) were following normal general 
education. Sixteen patients (16 %) were unemployed, with eight of these patients being 
unemployed due to mental and/or physical disability. Thirty patients (21 females) had 64 
healthy children. 
 
Mortality – Three patients with GSDIIIa had died because of cardiomyopathy: one patient 
because of severe congestive heart failure at the age of 1 year; and two patients because of 
sudden cardiac death due to progressive cardiac fibrosis at the age of 29 and 39 years, 
respectively (Ramachandran et al 2012). One patient with GSDIIIa died at the age of 36 years 
because of severe liver failure due to end-stage hepatic cirrhosis in combination with 




Dietary treatment at latest follow-up – Information regarding dietary treatment was collected 
on 171 patients (98 %; 87 children). Dietary restrictions were imposed on 16 patients; lactose 
restriction in ten patients and fat intake restriction in ten patients; 96 patients were reported to 
have a protein-enriched diet. In children (n = 49) the median cumulative protein intake was 2.9 
grams per kilogram bodyweight per day (gr/kg/d; range 0.5–4.4), and in adults (n = 47) the 
median cumulative protein intake was 1.7 gr/kg/d (range 0.9–3.0). Impaired dietary compliance 
was reported by the treating physician and/or dietician in at least 29 patients (17 patients 
aged < 25 years). 
 
History of dietary treatment – One hundred forty-six patients (83 %) were treated immediately 
after diagnosis. One hundred twenty-two patients were treated with uncooked cornstarch 
(UCCS) at some point; treatment with UCCS was stopped in 27 patients. Ninety-five patients 
were treated with UCCS at the latest dietary adjustment (64 patients age <18 years). Fifty-
seven patients were treated with continuous gastric drip feeding (CGDF) at some point; CGDF 
was stopped in 18 patients. Thirty-nine patients were treated with CGDF at the latest dietary 
adjustment (33 patients age <18 years). In total 17 patients had received no dietary treatment 




ISGSDIII is a descriptive, retrospective, international, multi-centre cohort study of 175 
patients. This study addresses important issues regarding clinical presentation and follow-up 
into adulthood. 
 
Before discussing the results, some methodological issues need to be addressed. First, as 
ISGSDIII is a retrospective study, we have predominantly collected cross-sectional rather than 
longitudinal patient data, and there has been missing data. Unfortunately, IGSDIII did not 
collect data on fasting tolerance. Second, the ISGSDIII cohort is still relatively young, and 








underrepresentation of long-term complications. Third, as most participating centres and 
colleagues are centre of expertise, selection bias towards relatively severely affected patients 
may have affected the results. Fourth, patients with the extremely rare subtypes GSDIIIc 
(presumably the result of glucosidase debranching deficiency) and GSDIIId (presumably the 
result of transferase debranching deficiency) have not been included. Last, despite the use of a 
CRF, in different centres clinical and laboratory data are not yet recorded in a standardized and 
quantitative manner (for instance dietary parameters, echocardiographic parameters, 
quantification of skeletal muscle strength and exercise tolerance). Particularly the availability 
of dietary management data has been very limited. It additionally needs to be recognized that 
there may be a difference between prescribed diets and daily practice. 
In contrast to the previous reports on GSDIII patients (Dagli et al 2010; Kishnani et al 
2010; Laforêt et al 2012), ISGSDIII demonstrates that hypoglycaemia is a presenting symptom 
in just half of the patients. Therefore, in patients with a traditional clinical (hepatomegaly) and 
biochemical (elevated transaminase values, hyperlipidaemia) presentation, the diagnosis of 
GSDIII should not be rejected in the absence of (severe) hypoglycaemia. In addition, the 
finding of ketotic hypoglycemia after short fasting test is a major argument for GSDIII, as 
demonstrated recently (Hoogeveen et al 2015). Severe mental retardation and mortality due to 
metabolic derangement are uncommon in GSDIII patients. ESGSDI has reported high 
morbidity and mortality because of metabolic derangements with hypoglycaemia (Rake et al 
2002). The difference between these studies may be partially explained by the relatively 
younger cohort of ISGSDIII. More importantly, there is a fundamental difference in metabolic 
compensation between GSDI patients (alternative lactate accumulates quickly, in the absence 
of ketones) and GSDIII patients (gluconeogenesis is intact and ketones can gradually be 
formed) during fasting. 
Clear genotype-phenotype correlations are rare in GSDIII. The association between 
exon 3 mutations and GSDIIIb has been reported previously (Shen et al 1996; Elpeleg 1999; 
Shen & Chen 2002; Goldstein et al 2010). Interestingly, non-missense AGL mutations are 
overrepresented in the ISGSDIII cohort, whereas in most metabolic diseases missense 
mutations predominate. It can be hypothesized that missense mutations in the large AGL gene 
cause only minor reduction of GDE enzyme activity. Moreover, ISGSDIII demonstrates that 
GSDIIIa patients display a more severe clinical course than GSDIIIb patients. The latter group 
clinically presents at a later stage and has fewer complications, such as hepatic cirrhosis and 
HCC. The large ISGSDIII cohort did not identify additional correlations between AGL 
genotype and severe complications. 
In accordance with previous reports (Vertilus et al 2010) ISGSDIII demonstrates that 
cardiac hypertrophy is common in GSDIIIa patients, mostly starting in the first decade of life 
(Fig. 2). Cardiac involvement remains stable over time in the majority of the affected patients, 
with even a portion of the patients regressing to normal values (data not presented). Hence, 
functional and clinically relevant hypertrophic cardiomyopathy is rare in GSDIIIa patients. 
Observations from GSDIIIa patients with severe hypertrophic cardiomyopathy suggest an 
important role of macronutrient intake (Derks & Smit 2015). To date it is speculative which 
macronutrient intervention is dominant, because each of the following has been described, i.e. 
decreased total caloric intake (Sentner et al 2012), increased protein intake (Dagli et al 2009; 
Sentner et al 2012), increased fat intake (Brambilla et al 2014), ketone bodies 
(Valayannopoulos et al 2011) and Atkins diet (Mayorandan et al 2014). It is not possible to 
draw causative conclusions from these single case observations, because increasing one 
macronutrient (either protein or fat) without affecting the other, inevitably affects the remaining 
macronutrient (carbohydrates). Based on at least two arguments it can be hypothesized that 
carbohydrate overtreatment may be an important risk factor for cardiac involvement and/or 
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macronutrient intervention is dominant, because each of the following has been described, i.e. 
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draw causative conclusions from these single case observations, because increasing one 
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cardiomyopathy. First, decreased carbohydrate intake was the intervention shared by the 
above-mentioned reports in which cardiomyopathy resolved after dietary intervention. 
Secondly, decompensated structural cardiomyopathy is most frequently reported around the 
time of highest endogenous glucose requirements (i.e. childhood) and the prescription of 
relatively high amounts of dietary carbohydrate. 
ISGSDIII demonstrates that GSDIII patients have (severe) growth retardation in (early) 
childhood, but eventually reach normal adult height. There is no significant difference in 
growth between GSDIIIa and GSDIIIb patients, suggesting that the metabolic demands on 
gluconeogenesis in GSDIII in general are more important than the presence of a muscular GDE 
deficiency. 
ISGSDIII demonstrates a high incidence of bone fractures in paediatric GSDIII patients, 
suggesting the development of reduced BMD at an early age. The pathophysiology of reduced 
BMD is unclear, but an association with specific nutritional deficiencies in GSDIII (Folk & 
Greene 1984; Kishnani et al 1999), and reduced metabolic control in GSDI (Rake et al 2003) 
are mentioned. Recently, ALAT has been suggested to be a marker for metabolic control in 
GSDIII (Dagli et al 2010). ISGSDIII demonstrates a negative correlation between 
osteopenia/osteoporosis and ALAT, supporting the hypothesis that metabolic control affects 
BMD. 
ISGSDIII reports a higher incidence of DM2 in ageing GSDIII patients than in the 
general population (i.e. 9 %: compared to 6 % in the general population in the western world 
according to the World Diabetes Foundation). Previous case reports and case studies have 
described the association between DM2 and GSDIII (Moe et al 1972; Oki et al 2000; Ismail 
2009; Sharma 2009; Spengos et al 2009) but the aetiology is largely unknown. In the ISGSDIII 
cohort, half of the diabetic patients are obese, suggesting that decreased insulin sensitivity 
might play a role. Second, the constant intake of carbohydrate enriched nutrients to maintain 





ISGSDIII presents large heterogeneity between individual GSDIII patients. Most GSDIII 
patients present clinically in their first year of life with hepatomegaly as the major presenting 
symptom. From an acute disease in childhood, GSDIII develops into a chronic, progressive 
disease in adulthood, affecting liver, heart, skeletal muscle and bones. Chronic complications 
and the risk of developing DM2 emphasize the need of closely following the ageing GSDIII 
cohort. Standardized quantitative clinical data collection is warranted by an international 
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International Study on Glycogen Storage Disease Type III Questionnaire 
__________________________________________________ 
0.1 Investigator 
0.2 Date of completing this form 
(ddmmyy) 
1.1 Initials patient 
1.2 Date of birth 
(ddmmyy) 
1.3 Informed Consent O no O yes 
1.4 Siblings with GSD III O no O yes 




2.3 Patients doctor 
3.1 Sex O male O female 
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__________________________________________________ 
0.1 Investigator 
0.2 Date of completing this form 
(ddmmyy) 
1.1 Initials patient 
1.2 Date of birth 
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2.3 Patients doctor 
3.1 Sex O male O female 
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4.1 O alive O deceased 
4.2 If alive 
Present treatment in your hospital O yes O no 
If no: name hospital of present  treatment : 
If yes : other hospital involved in treatment O no 
O yes: name: 
address: 
4.3 If deceased    Date of death (ddmmyy) 
Cause of death : 
Based on clinical date : 
Pathological findings: 
5 - Pregnancy and birth 
5.1 Complications in 
pregnancy 
O no O yes : 
5.2 Complications at 
birth 
O no O yes : 
5.3 Gestational age 
Weeks 
5.4 Birth weight 
Grams 
6 - First symptoms 
6.1 First symptom 
Hypoglycemia O no O yes 
Hepatomegaly O no O yes 
Developmental delay O no O yes 
Biochemical 
abnormalities 
O no O yes, details: 
Other O no O yes, details: 
6.2 At the age of 
(ddmmyy ) 
6.3 At the age of 
(ddmmyy) 
53 
7 - Diagnosis 
7.1 Clinical diagnosis O GSD III with myopathy 
O GSD III without myopathy 
7.2 Based on Histology Liver biopsy O yes O no 
If yes Date 
(mmyy)        
Name centre 
Muscle biopsy O yes O no 
If yes 
Date 
(mmyy)       
Name centre 
7.3 Based on Enzymatic Diagnosis 
Amilo-1.6 glucosidase deficiency in white 
blood cells 
O yes O no O not done 
Amilo-1.6 glucosidase deficiency in liver O yes O no O not done 
Amilo-1.6 glucosidase deficiency in muscle O yes O no O not done 
State subtype of GSD III (if tested) 
Elevated RBC’s Glycogen O yes O no O not done 
7.4 Mutation analysis State mutation if known : O not done 
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8 - Dietary history & farmacological treatment 
8.1 Dietary history until the age of 25 years Point out in 
figure A 
8.2 If age > 25 years: alterations in dietary treatment 
after the age of 25  
O no O yes 
 If yes : alteration : At the age of  :   
               (years) 
              
              (years) 
                      
               (years) 
8.3 Comments on dietary history :  
 
8.4 Farmacological treatment until the age of 25 
years 
Point out in  
figure A 
8.5 If age > 25 years: alterations in farmacological 
treatment after the age of 25  
O no O yes 
 If yes : alteration : At the age of  :   
                (years) 
                (years) 
                (years) 



























9 - Growth 
9.1 Nationality : 
9.2 Ethnic group  O Asian O Caucasian O Mediterrenean 
           O Negroid O other, nl :  
9.3 Parental height Father: (cm) Mother: (cm) 
9.4 Growth until the 
age of 23 years 
9.4.1 Height (cm) Fill in figure B 
(physical – 
examination)  9.4.2 Height (SD’s) * 
9.4.3 Weight (kg) 
9.5 Adult height                     (cm), reached at             (age in years)                                                          
9.6 Pubertal development 
 
O not relevant, too 
young 
O unknown 
 O early ** O normal  O late *** 
 If female, menarche at 
the age of 
               (years) O unknown 
9.7 Bone-age measurement O no O yes  




*       SD’s according to the standards of the country of origin. 
**     Before 8 years in girls or 9 years in boys. 
***   After 14 years in girls or 15 years in boys. 
 
 
10 - Hypoglycemia 
10.1 Admissions because of convulsions and/or coma due to documented 
hypoglycemia in each period  
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11 - Hyperlipidemia 
11.1 Blood cholesterol Fill in figure C  (laboratory investigations 
blood) 
11.2 Blood triglycerides 
11.3 O no O yes, at the age of (years) 
If yes, course : 
11.4 Atherosclerosis O no O yes, at the age of (years) 
O yes , at autopsy 
If yes, course, symptoms and findings :  
12 - Hepatic complications 
12.1 Cirrhosis O no O yes, at the age of (years) 
Course : 
12.2 Hepatic adenomas O no O yes, first detected at the age of    
(years)
O single one O multiple 
Course : 
13 - Osteopenia 
13.1 Pathological fractures O no O yes,  at the age of (years) 
If yes, course: 
57 
14 - Psychosocial 
14.1 Mental development O low 
{IQ < 65} 
O borderline 
{IQ 65-85} 
O normal  
{IQ 85-115} 
O  high 
{IQ>115} 
Current school or most recent finished school : 
14.2 If working – age O unemployed 
O employed, profession : 
14.3 Married or long – 
standing relationship 
O not relevant O no O yes 
14.4 Children O not relevant O no O yes, number 





O no O yes at the age of 
(years) 
15.2 Abnormal Echocardiogram O not 
assessed 
O no O yes at the age of
(years) 
Details: 
Progression O no O yes 
15.3 Clinical signs of heart 
failure  
O no O yes at the age of (years) 
15.4 Requirement of medical 
therapy  
O no O yes, started at the age of
(years) 
15.5 Heart transplantation O no O yes at the age of (years) 
15.6 Coronary heart disease O no O yes at the age of (years) 
15.7 Angina pectoris O no O yes at the age of (years) 
15.8 Myocardial infarction O no O yes at the age of (years) 
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16 - Neuromuscular  
16.1 Hypotonia in family  O no O yes  
16.2 Delayed walking * O no O yes  
16.3 Proximal myopathy, 
muscular wasting   
O no O yes, at the age of                (years) 
16.4 Muscle pain O no O yes 
16.5 Distal myopathy  O no O yes, at the age of                (years) 
16.6 Exercise Intolerance O no O yes  
 Details: 
 
16.7 EMG (Electromyogram) O not 
assessed 
O normal O abnormal at the age of                      
 Details: 
  




O normal O abnormal, details : 
 
* after 18 months of age. 
 
 
17 - Endocrinology 
17.1  Diabetes mellitus / Insulin 
resistance 
O no O yes,  if yes type : 
 Age of onset                
                                    (years) 
 State initiated therapy: 
 
 
17.2  Hirsutism O no O yes  
17.3  Irregular menses/Amenorrhea O no O yes  












18 - Renal Function 
18.1 Renal Function O not 
assessed 
O normal O abnormal, details: 
Age of onset (years)
18.2 Tubular Dysfunction O no O yes, details: 
18.3 Glomerular Dysfunction O no O yes, details: 
18.4 Renal Tubular Acidosis O no O yes, state type: 
Age of onset ( years) 
18.5 Other Kidney abnormalities O no O yes, details: 
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Figure A Dietary history & farmacological treatment 
 
Point out the dietary history (till the age of 25 years) in this figure.  
Abbreviations used:  
FM   frequent meals 
CS  cornstarch added to the meals 
GDF  gastric drip feeding 
TCS  total cornstarch supplementation in grams per kilogram of bodyweight 
TPS  total protein supplementation in grams per kilogram of bodyweight 
CS1   cornstarch once a night (f.e. before going to sleep)  
CS2  cornstarch two times a night (f.e. before going to sleep and at 3.00 a.m.) 
H.P.   high protein diet  
F.T.                 farmacological treatment 
 
 
Age (years) 0.5 1 2 3 4 5 6 7 8 9 10 11 12 
Day  FM              
   CS              
GDF              
TCS              
TPS              
Nights FM              
 CS1              
CS2              
GDF              
TCS              
TPS              
                 H.P.              
                 F.T.              
Age (years) 13 14 15 16 17 18 19 20 21 22 23 24 25 
Day FM              
 CS              
GDF              
TCS              
TPS              
Nights FM              
 CS1              
CS2              
GDF              
TCS              
TPS              
                 H.P.              
                 F.T.              
61 
Figure B Physical Examination 
Fill in date of examination, height in cm, height in standard deviation score (SDS, if 
known), weight in kg and liver in cm below the costal margin in the midclavicular line. 
* SD’s according to the standards of the country of origin.





Liver in m.c.l 
b.c.m





Liver in m.c.l 
b.c.m





Liver in m.c.l 
b.c.m
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Figure C Laboratory investigations blood 
Fill in date of investigation, blood cholesterol, triglycerides, uric acid, haemoglobin, and 
hematocrit, mean corpuscular volume (MCV), calcium, creatinin, cholinesterase, alpha-
fetoprotein, troponin, AST, ALT, creatine kinase, CK-MB, CK-MM and state which units are 
used in each investigation (e.g. mmo1/1).  
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Figure C Laboratory investigations blood 
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Chapter 4 
Hyperlipidemia in glycogen storage disease type III: effect of 
age and metabolic control 
Angelina V. Bernier, Christiaan P. Sentner, Catherine E. Correia, 
Douglas W. Theriaque, Jonathan J. Shuster,  
G. Peter A. Smit, David A. Weinstein
Journal of Inherited Metabolic Disease 2008 Dec;31(6):729-32. 
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While the presence of hyperlipidaemia in glycogen storage disease (GSD) type Ia and Ib is 
generally accepted, few investigators have adequately assessed lipid profiles of GSD III in 
children, in whom the presence of hyperlipidaemia may be most prominent. We analysed the 
lipid profiles in 44 GSDIII patients from 6 months to 30 years of age. Hypertriglyceridaemia 
and hypercholesterolaemia were common in children younger than 3 years of age. 
Hypertriglyceridaemia correlated negatively with age, and may reflect increased severity of 
hypoglycaemia in this younger population. The presence of hyperlipidaemia during childhood 
in these patients identifies another GSD population that could be at risk for early cardiovascular 
disease (CVD). Consequently, the outcome of clinical trials investigating the vascular effect of 










Type III glycogen storage disease (GSDIII; OMIM 232400) results from a defect in glycogen 
debranching enzyme (GDE) that interrupts glycogenolysis. In the first step of glycogenolysis, 
glycogen phosphorylase and GDE remove glucose from the outer branches of glycogen to form 
glucose 1-phosphate. Impairment of GDE leads to the accumulation of an abnormal form of 
glycogen, limit dextrin, in liver, heart and skeletal muscle. As the biochemical abnormalities 
in GSDIII are present in these affected organs, creatine kinase (CK), aspartate transaminase 
(ASAT) and alanine transaminase (ALAT) are used as markers of control in the management 
of this disorder (Wolfsdorf and Weinstein 2003). 
In the United States, 80% of patients with GSDIII have liver, heart and skeletal muscle 
involvement (type IIIa), while most of the remaining patients have only liver involvement (type 
IIIb). The predominant manifestation of GSDIII in infancy and childhood is hypoglycaemia 
with fasting. As patients age, however, muscle damage occurs (type IIIa), and most patients 
have severe physical limitations by the fourth decade of life (Wolfsdorf and Weinstein 2003). 
Unlike the other hepatic GSDs, researchers debate the presence of hyperlipidaemia in 
GSD III. Geberhiwot et al (2007) described the lipid profiles in GSD I, III and IX. He found 
evidence of pro-atherogenic lipid profiles in GSDIa characterized by hypercholesterolaemia, 
hypertriglyceridaemia and reduced HDL. However, he found no significant abnormalities in 
the lipid profiles of a cohort of six patients with GSDIII aged 14–to 54 years. Likewise, 
Hershkovitz et al (1999) reported no abnormality of plasma lipid and lipoprotein profile in 11 
GSDIII patients aged 17–54 years. Despite this evidence, the small number of patients studied 
does not yet justify the conclusion that GSDIII patients have no risk for hyperlipidaemia. 
Given that the majority of studies reviewing hyperlipidaemia in GSDIII do not include 
patients younger than 14 years of age, in whom hypoglycaemia is most severe, we analysed 
the largest collection of GSDIII patient data available. We ascertained the prevalence of 
hyperlipidaemia in GSDIII at all ages. We postulated that hyperlipidaemia correlates with 




Design – The study was based on a secondary analysis of patient data recorded through the 
collaborative International Study on GSDIII (ISGSDIII) database. This database was designed 
to collect outcome data of natural history and clinical interventions to develop clinical 
guidelines and therapeutic strategies for GSDIII. Clinical and laboratory data from participants 
are entered annually into this longitudinal database. We included results for total cholesterol, 
triglycerides and ALAT. These data were analysed within five age groups that were defined 
before the analysis: 0–3, 3–6, 6–12, 12–18, and greater than 18 years. 
 
Participants – The diagnosis of GSDIII was established either by histological examination of 
liver biopsy specimens or by enzymatic methods and, more recently, through mutation analysis 
of DNA obtained from a blood or saliva sample. IRB approval was obtained for the collection 
of data in the ISGSDIII database, and informed consent with assent of minors was obtained 
from all participants. 
A total of 44 patients (32 GSDIIIa and 12 GSDIIIb) identified from hospital records of 16 
metabolic centres in eight countries had a complete set of variables with 204 observations. A 
quality review check by looking at date of birth and initials ensured that no participant was 
duplicated. Data from patient records were compiled by either the treating physician or one of 
the investigators. In order to assess changes with time, at least two observation times were 
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needed for inclusion of a patient in the analysis. There were 32 individuals with multiple time 
points for triglycerides and 30 with multiple time points for cholesterol. 
Statistical methods – The key inferences were based on personal linear regression slopes to see 
whether the quantitative outcomes (serum triglycerides and serum cholesterol) were changing 
over time. Since these may be outlier-prone, we used the Wilcoxon signed-rank test, which is 
stable against such outliers, to compare with a null value of zero slope in the target population. 
Secondarily, we correlated the fitted slopes for triglycerides with ALAT to see whether the 
changes tended to be concordant (positive association) versus discordant (negative association) 
by the Spearman rank correlation test. All reported p-values are two-sided. 
For descriptive purposes, we also provide means and standard deviations for outcomes 
by age period. To avoid bias, each subject was weighted equally, regardless of the number of 
observations in the reporting period. The participant’s individual mean for the age period was 
used as the outcome. This method was also applied to estimate the prevalence of 
hypertriglyceridaemia and hypercholesterolaemia, which are 0=no or 1=yes at each 
participant’s observation point in the age group. 
Results 
Triglycerides – Prevalence of hypertriglyceridaemia (defined as >1.69 mmol/L) was estimated 
to be 67% (standard error=6%; Table 1). Elevated triglyceride concentrations, however, were 
most commonly found in younger children (Fig. 1), with a significant decrease in triglycerides 
with increasing age (p=0.026). Approximately 75% of the subjects had a negative slope and 
the median slope was −0.11 mmol/L per year. 
Table 1 Prevalence of hypercholesterolaemia and hypertriglyceridaemia by age. This table demonstrates the 
prevalence of both hypercholesterolaemia and hypertriglyceridaemia within pre-determined age brackets. The 











0.0 – 3.0 19/19 58% (10%) 89% (6%) 
3.0 – 6.0 15/14 33% (12%) 86% (8%) 
6.0 – 12.0 18/17 51% (11%) 87% (7%) 
12.0 – 18.0 15/16 22% (9%) 63% (12%) 
> 18.0 16/16  22% (9%) 44% (11%) 
Cholesterol – Prevalence of hypercholesterolaemia (defined as total cholesterol >5.17 mmol/L) 
was estimated to be 31% (standard error=6%; Table 1). Unlike triglycerides, however, the 
elevated cholesterol concentrations did not demonstrate an age predilection (Fig. 2), nor did 
absolute cholesterol concentrations significantly associate with age (p=0.59) with a median 
slope of −0.02 mmol/L per year. 
Markers of control – Spearman correlation analysis of the individual slopes with age revealed 









Figure 1 Triglyceride box-and-whisker plot. Boxes represent the 25th to 75th percentiles, and the median is 
represented in each box. The range of the observations is depicted by the whiskers. The dotted line represents the 
cut-off for hypertriglyceridemia defined as >1.69 mmol/L (150 mg/dl). One observation – the mean of multiple 




Figure 2 Total cholesterol box-and-whisker plot. Boxes represent the 25th to 75th percentiles, and the median 
is represented in each box. The range of the observations is depicted by the whiskers. The dotted line represents 
the cut-off for hypercholesterolemia defined as >5.17 mmol/L (200 mg/dl). One observation – the mean of 







Hyperlipidaemia in the hepatic GSDs develops from a combination of two mechanisms. The 
first, specific to GSDI, results from shunting of glycogen breakdown products through the 
glycolytic pathway, which increases formation of acetyl-CoA and synthesis of fatty acids and 
cholesterol in the liver (Bandsma et al 2008). The second mechanism, which occurs in GSD 
VI and IX, results from increased β-oxidation of fats in the setting of hypoglycaemia that, in 
turn, increases fatty acid flux from adipose tissue to the liver as an alternative source of fuel. 
This second mechanism is hypothesized to result in the observed hyperlipidaemia in GSDIII. 
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needed for inclusion of a patient in the analysis. There were 32 individuals with multiple time 
points for triglycerides and 30 with multiple time points for cholesterol. 
Statistical methods – The key inferences were based on personal linear regression slopes to see 
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Although the circumstances responsible for hyperlipidemia in other types of GSD are present 
in GSDIII, hypertriglyceridaemia has not previously been characterized in children with this 
form of GSD. The inability to mobilize glycogen results in frequent hypoglycaemia in affected 
children. This frequency of hypoglycaemia in GSDIII patients, however, decreases with age, 
which may explain why previous investigations did not reveal lipid abnormalities in this 
population. 
With improving dietary management, patients with GSD are living well into adulthood. 
Patients with GSDI and III commonly reach ages where the potential contribution of 
hyperlipidaemia to the development of atherosclerosis becomes important. However, even 
though GSDI patients manifest a pro-atherogenic lipid profile characterized by 
hypercholesterolaemia, hypertriglyceridaemia, and reduced HDL, investigations have not 
demonstrated an increased frequency of cardiovascular disease (CVD) in this population 
(Ubels et al 2002). On the basis of early studies (Muhlhausen et al 2005; Nguyen et al 2006; 
Wittenstein et al 2002) that failed to establish a correlation between GSD patients with 
hyperlipidaemia and risk of early CVD, the current consensus guideline for management of 
GSDI does not mandate treatment with lipid-lowering agents unless patients are at risk for 
pancreatitis. Researchers have attempted to explain the apparent protective features of GSDI 
by proposing mechanisms such as increased cholesterol efflux, increased antioxidant potential, 
and decreased platelet aggregation (Muhlhausen et al 2005; Nguyen et al 2006; Wittenstein et 
al 2002). However, these hypotheses have been developed on the basis of very few patients. 
Unlike in patients with GSDI, hypertriglyceridaemia in GSDIII does not reach levels 
high enough to cause pancreatitis. Indeed, pancreatitis has not been described in GSDIII, and 
treatment for elevated lipids may be less likely to be commenced. Nevertheless, the potential 
risk of elevated triglycerides has yet to be determined, especially regarding risk for vessel 
dysfunction and CVD. If vascular dysfunction does occur, aggressive treatment is warranted. 
Future studies in the GSDIII population are therefore needed to determine whether the elevated 
lipids in GSDIII are pro-atherogenic and, if so, whether pharmacological therapy will decrease 
the risk of CVD. 
Limitations of this study arise from the lack of information regarding dietary therapy in 
this population. In addition, only total cholesterol and triglycerides were included in the 
database, while HDL and LDL were omitted, resulting in incomplete assessment of 
cardiovascular risk. Finally, while this study represents the largest assessment of 
hyperlipidaemia in GSDIII, the numbers are still relatively small, and an assessment of lipids 
in the subtypes of GSDIII could not be performed. Despite these limitations, hyperlipidaemia 
clearly occurs in this population, and a more thorough evaluation of cardiovascular risk factors 
is needed as part of new prospective studies assessing CVD. 
 
In conclusion, hyperlipidaemia occurs in children with GSDIII. The duration of this metabolic 
derangement throughout childhood may place adolescent and adult patients at risk for CVD. 
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In glycogen storage disease type III (GSDIII) deficiency of the debranching enzyme causes 
storage of an intermediate glycogen molecule (limit dextrin) in the affected tissues. In subtype 
IIIa hepatic tissue, skeletal- and cardiac muscle tissue is affected, while in subtype IIIb only 
hepatic tissue is affected. Cardiac storage of limit dextrin causes a form of cardiomyopathy 
which resembles primary hypertrophic cardiomyopathy on cardiac ultrasound. We present a 32 
year-old GSDIIIa patient with severe left ventricular hypertrophy (LVH) first diagnosed at the 
age of 8 years. LVH remained stable and symptomless until the patient presented at age 25 
years with increasing dyspnoea, fatigue, obesity, and NYHA (New York Heart Association) 
functional classification 2 out of 4. Dyspnoea, fatigue, and obesity progressed, and at age 28 
years she was severely symptomatic with NYHA classification 3+ out of 4. On echocardiogram 
and electrocardiogram the LVH had progressed as well. Initially she was rejected for cardiac 
transplantation because of severe obesity. Therefore, a 900 calorie, high protein diet providing 
37% of total energy, was prescribed during four months on which 10 kilograms weight loss 
was achieved. However, her symptoms as well as the electrocardiographic and 
echocardiographic LVH indices had improved dramatically – ultimately deferring cardiac 
transplantation. Thereafter the caloric intake was increased to 1370 calories per day, and the 
high protein intake was continued providing 43% of total energy. After three years of follow-




Glycogen storage disease type III (GSDIII) is an autosomal recessive disorder in which a 
mutation in the AGL-gene causes deficiency of the glycogen debranching enzyme (GDE). The 
DE consists of two active centres, which catalyze the last step in the conversion of glycogen to 
glucose (Smit et al 2006). The absence of DE activity in GSD III patients causes storage of an 
intermediate form of glycogen, limit dextrin (LD) (Chen 2001). 85% of the GSDIII patients 
have subtype IIIa in which GDE is deficient in muscle and liver tissue. 15% of the patients 
have subtype IIIb in which GDE is deficient in the liver (Shen et al 1996). In neonates and 
infants the main features are hepatomegaly, keto-hypoglycemic episodes after short periods of 
fasting, and hyperlipidemia. Poorly treated neonates and children have developmental delay, 
growth retardation and delayed puberty. Proximal and distal myopathy presents in adult 
GSDIIIa patients, which may be enforced by the development of peripheral neuropathy 
(Wolfsdorf and Weinstein 2003). Cardiomyopathy is a frequent complication in GSDIIIa since 
LD can also store in myocardial cells and between bundles of myofilaments (Moses et al 1989; 
Smit et al 1990; Labrune et al 1991; Coleman et al 1992; Carvalho et al 1993; Talente et al 
1994). This causes a form of cardiomyopathy that echocardiographically resembles primary 
hypertrophic cardiomyopathy due to sarcomere gene mutations, but shows a different response 
to exercise testing, 24-hour electrocardiographic monitoring and thallium-201 myocardial 
scintigraphy (Lee et al 1997; Akazawa et al 1997; Olson et al 1984).  The clinical significance 
and long-term consequences of GSDIIIa related cardiomyopathy are unclear due to a lack of 
data and experience. 
The aim of the dietary treatment of GSDIII is to divide the carbohydrate intake 
throughout the day to maintain normoglycemia by taking frequent meals and regular cornstarch 
doses (Gremse et al 1990). Protein supplementation is necessary as it serves as a substrate for 
gluconeogenesis during fasting conditions and improves myopathy and growth failure (Slonim 
et al 1982; Slonim et al 1984; Kiechl et al 1999). However, there is no consensus between 
centres on the usage of a high protein diet or the amount of cornstarch that should be provided. 
In this case-report we present a GSDIIIa patient with severely symptomatic 
hypertrophic cardiomyopathy which was reversed after initiating a low-calorie, high protein 
diet to achieve weight loss for a cardiac transplantation preparation program. Subsequently her 
cardiomyopathy-related symptoms and signs improved dramatically and cardiac 
transplantation could be deferred. 
Case Report 
The patient reported is a 32 year-old Turkish female born to consanguineous parents after an 
uncomplicated pregnancy and birth. She was diagnosed with glycogen storage disease in 
Turkey at a young age, but subtyping for GSDIII was only initiated at the age of 8 years after 
she moved to the Netherlands. Enzymatic measurements confirmed absent DE activity in 
muscle- and liver tissue, confirming GSDIIIa. Genetic mutation analysis revealed a pathologic 
homozygote 4 basepair deletion in exon 7 of the AGL gene (GeneBank genomic reference 
sequence NW_012865) c.753_756delCAGA causing a frameshift (Lucchiari et al 2006). Upon 
clinical evaluation the main findings were hepatomegaly with elevated aspartate transaminase 
(203 U/L), alanine transferase (253 U/L), triglycerides (1,7 mmol/L) and creatin kinase values 
(2112 U/L). A grade III out of VI systolic cardiac murmur was heard in the 4th left intercostal 
space. Further cardiac evaluation revealed hypertrophic cardiomyopathy with concentric left 
ventricular hypertrophy (LVH). On the ECG no rhythm- or conduction disturbances were seen. 
Following diagnosis, dietary treatment was initiated with protein-enriched frequent meals 
during the day and one late night meal. She responded well to treatment and no hypoglycaemic 
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episodes requiring hospitalisation have occurred since. During puberty the liver size 
normalized, but the transaminase values remained elevated. Echocardiographically the LVH 
remained stable and symptomless, therefore no further cardiologic follow-up was deemed 
necessary. 
At age 25 years the patient presented in the outpatient-ward with increasing dyspnoea, 
fatigue, obesity, and functional classification according to the New York Heart Association 
(NYHA) 2 out of 4 (table 1). At physical examination, her heart rate was 69 bpm, blood 
pressure 100/60 mmHg, with mild jugular venous pressure elevation. Her electrocardiogram 
showed increased QRS-voltage and -duration with negative T-waves comparable with severe 
LVH (figure 1). The Sokolow-Lyon-, Cornell Voltage- and Romhilt-Estes electrocardiographic 
indices for LVH were all positive (figure 1). The echocardiogram showed severe concentric 
LVH with intraventricular septum (IVS) thickness of 22 mm, and a posterior wall (PW) 
thickness of 18 mm with normal dimensions (table 1). She was treated with low-dose 
furosemide, fluid restriction, and her diet was adjusted to provide extra protein during the day. 
Also,  a  late  night  feed  combined  with cornstarch was added to ensure normoglycemia 
during the night. In the following years the symptoms of dyspnoea and fatigue slowly 
progressed, and she gained weight. At age 28 years, she was severely symptomatic with a 
NYHA functional class of 3+ out of 4. The patients’ BMI increased to 32.2 because she avoided 
physical exercise as this provoked palpitations and chest pain. The electrocardiographic and 
echocardiographic LVH indices worsened accordingly (IVS thickness 32mm, PW thickness 
25mm). At that time lowdose perindopril and carvedilol to the furosemide, and a prophylactic 
implantable cardioverter defibrillator was placed due to an increased risk of sudden cardiac 
death. 
Table 1 Clinical symptoms, laboratory and echocardiographic results over time. 
Age (years) 25 26 27 28 29 30* 31* 32* 
BMI ! 29.7 29.7 30.9 30.3 32.2 30.5 27.7 27.8 
Dyspnea § + + + ++ ++ - - - 
Chest Pain § ± ± ± + ++ - - - 
Fatigue § ++ + ++ ++ ++ + + + 
Palpitations § - - - ± + - - - 
NYHA classification @ 2 2 2 3+ 3+ 2 2 2 
Creatin Kinase (U/L) 578 1368 1537 3662 2712 849 1449 1400 
Echocardiographic measurements (mm) 
IVS ˆ 22 27 32 28 32 29 22 21 
PW + 18 23 24 29 25 25 25 25 
LA # 34 31 33 41 42 47 47 48 
LVED $ 49 45 46 42 43 43 44 49 
LVES % 30 34 29 27 30 28 31 33 
* Bold numbers indicate data after the introduction of a high-protein, low calorie diet at the age of 30 years
! BMI indicates body mass index
§ indicates no symptoms; ± minor symptoms; + indicates intermittent symptoms; ++ indicates daily symptoms
@ NYHA classification indicates functional classification for heart failure by the New York Heart Association
^ IVS indicates interventricular septum
+ PW indicates lef ventricular posterior wall
# LA indicates left atrial dimensions
$ LVED indicates left ventricular end-diastolic dimensions
% LVES indicates left ventricular end-systolic dimensions
Due to the worsening situation the patient was evaluated for heart transplantation (HTX) at the 
age of 30 years. Therefore, a pre-HTX program was set up consisting of: 1. evaluation of the 
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status of liver and skeletal muscle, 2. a new dietary regimen to reduce weight by 10 kg, 3. peri-
operative advice regarding the management of GSD III during the HTX. The new dietary 
regimen consisted of 24-hour protein-enriched naso-gastric drip feeding containing 900 
calories per day, with protein providing 37%, carbohydrates 61%, and lipids 2% providing of 
total energy. After following the new dietary regimen for four months her BMI decreased to 
27.7, along with a significant improvement of her complaints of constant fatigue and exercise 
intolerance. The NYHA classification decreased accordingly to 2 out of 4. On cardiac 
ultrasound concentric LVH was still present but the PW and IVS thickness had decreased to 
25mm and 24mm respectively, along with the electrocardiographic LVH indices. Consequently 
the patient was taken off the pre-HTX program, and cardiac transplantation was deferred. The 
caloric intake was increased to 1370 calories per day, and the continuous naso-gastric drip 
feeding was stopped. The dietary regimen was switched to seven meals at daytime with two-
hour intervals. Five of these meals were drinks, and two were normal meals, which were 
comparable in composition of energy and protein to the drinks. In the nocturnal period two 
gifts of cornstarch were added to reach a four-hour interval between meals. The high protein 
nature of the diet was maintained, and even increased to provide 43% of total energy per day 
compared to 37% protein per day during the pre-HTX program. After three years of follow-up 
she remains satisfied with reasonable exercise tolerance and minor symptoms in daily life. 
Figure 1 Twelve-lead electrocardiograpy showing severe left ventricular hypertrophy with secondary  
repolarisation abnormalities at the age of 25, 29, 30 and 32 years old. 
Discussion 
We report a severely symptomatic GSDIIIa patient with cardiomyopathy who improves 
clinically and objectively on a high protein diet with a limited supply of carbohydrates. To our 
knowledge, a similar case has been reported recently in a pediatric patient (Valayannopoulos 
et al 2011), and once in an adult patient by Dagli et al in 2009. The latter describes a 22 year-
old male with severe GSDIII related cardiomyopathy treated with a high protein diet in which 
overtreatment with cornstarch was avoided. Their patient improved dramatically with reversal 
of symptoms and echocardiographic signs of hypertrophic cardiomyopathy. 
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@ NYHA classification indicates functional classification for heart failure by the New York Heart Association
^ IVS indicates interventricular septum
+ PW indicates lef ventricular posterior wall
# LA indicates left atrial dimensions
$ LVED indicates left ventricular end-diastolic dimensions
% LVES indicates left ventricular end-systolic dimensions
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The physiology of the reversal of extreme LVH in GSDIIIa is not clear. A direct effect, where 
the limited supplementation of carbohydrate and increased usage of protein in gluconeogenesis 
reduces the cardiac storage of LD is feasible. An indirect effect is also feasible where the weight 
reduction reduces fat disposition in skeletal muscles, improving the condition and possible 
workload of the skeletal muscles and reducing the workload on the heart (Kelley et al 1991; 
Goodpaster et al 1999). A combination of these effects is also possible. 
The majority of the patients seem to remain asymptomatic and the cardiomyopathy 
seems to be non-progressive (Lee et al 1997). Therefore, severe cases such as these emphasize 
the need for regular cardiac follow-up in patients with GSDIIIa related cardiomyopathy, along 
with the benefits of a high protein diet. In our population of GSDIII patients a high protein diet 
is implemented at a young age and continued through into adulthood. Through these dietary 
regimens GSDIII patients usually derive 20-30% of total energy from protein, which varies 
from four grams of protein per kilogram body weight in children and adolescents, to two grams 
of protein per kilogram body weight in adult patients. Therefore, renal function is also closely 
monitored during follow-up of these patients. 
This report presents the first case of a GSDIIIa patient in whom cardiac transplantation 
could be deferred after initiating a low calorie, high protein diet. In younger unaffected 
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In glycogen storage diseases (GSDs), improved longevity has resulted in the need for 
neuromuscular surveillance. In 12 children and 14 adults with the ‘‘hepatic’’ (GSDI) and 
‘‘myopathic’’ (GSDIII) phenotypes, we cross-sectionally assessed muscle ultrasound density 
(MUD) and muscle force. Children with both ‘‘hepatic’’ and ‘‘myopathic’’ GSD phenotypes 
had elevated MUD values (MUD Z-scores: GSDI > 2.5 SD vs. GSDIII > 1 SD, p < 0.05) and 
muscle weakness (GSDI muscle force; p < 0.05) of myopathic distribution. In ‘‘hepatic’’ GSDI 
adults, MUD stabilized (GSDI adults vs. GSDI children, not significant), concurring with 
moderate muscle weakness (GSDI adults vs. healthy matched pairs, p <0.05). In ‘‘myopathic’’ 
GSDIII adults, MUD increased with age (MUD-GSD III vs. age: r = 0.71–0.83, GSDIII adults 
> GSDIII children, p < 0.05), concurring with pronounced muscle weakness (GSDIII adults vs.
GSDI adults, p < 0.05) of myopathic distribution. Children with ‘‘hepatic’’ and ‘‘myopathic’’
GSD phenotypes were both found to have myopathy. Myopathy stabilizes in ‘‘hepatic’’ GSDI
adults, whereas it progresses in ‘‘myopathic’’ GSDIII adults. Muscle ultrasonography provides
an excellent, non-invasive tool for neuromuscular surveillance per GSD phenotype.
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Introduction 
Glycogen storage diseases (GSD) concern a heterogeneous group of inborn errors of glycogen 
metabolism and/or gluconeogenesis (Dagli et al 2012; Kishnani et al 2014; Laforêt et al 2011). 
Depending on enzyme deficiency and tissue distribution, GSDs are subdivided into ‘‘hepatic’’ 
and ‘‘myopathic’’ phenotypes. ‘‘Hepatic’’ phenotypes are associated with an underlying 
glycogenolysis and/or gluconeogenesis defect, causing hepatic glycogen storage and 
insufficient endogenous glucose production (Laforêt et al 2011). Myopathic phenotypes are 
associated with defective muscle glycogenolysis and/or glycolysis (van Adel & Tarnopolsky 
2009), causing myopathy, muscle cramps (GSDV) and respiratory insufficiency (GSDII) (van 
Adel & Tarnopolsky 2009).  
Glycogen storage disease type I (glucose-6- phosphatase deficiency, OMIM [Online 
Mendelian Inheritance in Man] Nos. 232200 and 232220) concerns a ‘‘hepatic’’ phenotype 
with hepatic glycogen storage and non-ketotic hypoglycemia. Although glucose-6- 
phosphatase is not expressed in muscles, it is well known that GSDI patients may still manifest 
myopathic features (muscle weakness and atrophy) (Huidekoper et al 2010; Schwahn et al 
2002). However, specific insight into these myopathic GSDI features is still lacking.  
Glycogen storage disease type III concerns a ‘‘mixed-myopathic’’ phenotype 
(OMIM#23400), caused by a glycogen-debranching enzyme (GDE) gene mutation (amylo-a-
1,6-glucosidase,4-a-glucanotransferase), resulting in limited dextrin storage (Yang-Feng et al 
1992). According to differential splicing of the GDE gene, GSDIII is characterized by IIIa and 
IIIb subtypes. The ‘‘myopathic’’ GSDIIIa subtype is associated with progressive liver, heart 
and neuromuscular impairment, resulting in liver cirrhosis, hypertrophic cardiomyopathy and 
ambulation loss (Dagli et al 2012; Hobson-Webb et al 2010; Momoi et al 1992). Interestingly, 
the GSDIIIb subtype is characterized as a ‘‘hepatic’’ instead of ‘‘myopathic’’ phenotype (Shen 
& Chen 2002; Talente et al 1994), despite myopathic electromyography (EMG) alterations 
(Hobson-Webb et al 2010). In GSDIII patients, muscle nuclear magnetic resonance 
spectroscopy (NMRS) revealed that muscle weakness occurs with muscle glycogen 
accumulation and fat deposition (Wary et al 2010). It is still unclear whether such myopathic 
alterations are paralleled by elevated blood creatine kinase (CK) levels (Mogahed et al 2015), 
or not (Hobson-Webb et al 2010).  
For improved longevity and quality of life, moderate physical exercise and clinical 
neuromuscular surveillance seem recommendable (Mogahed et al 2015; Murphy et al 2005; 
Vertilus et al 2010). However, insight into the progression of neuromuscular symptoms during 
the natural disease course is still sparse.  
The non-invasive muscle ultrasound technique can detect pathologic muscle conditions, 
including muscle glycogen and fat deposition, by the enhanced reflection of the muscle 
ultrasound beam (quantified by increased muscle ultrasound density (MUD)) (Maurits et al 
2003, 2004; Pillen et al 2007, 2008; Verbeek et al 2012, 2014). In this respect, muscle 
ultrasound may provide an excellent diagnostic tool in GSD patients. Because the technique is 
applicable to the bedside with little cooperation of the patient, it can easily be performed in 
young children, avoiding the necessity for more invasive procedures (such as EMG with needle 
electrodes, muscle biopsy and/or magnetic resonance imaging requiring anesthesia). To the 
best of our knowledge, muscle ultrasound studies have not been performed in GSD patients 
before.  
In children and adults with GSDI and GSDIII subtypes, we aimed to assess and compare 
MUD with other neurophysiologic and clinical neuromuscular disease parameters, involving: 
EMG neurography, dynometry, CK values and subjective neuromuscular complaints. 
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Vertilus et al 2010). However, insight into the progression of neuromuscular symptoms during 
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The non-invasive muscle ultrasound technique can detect pathologic muscle conditions, 
including muscle glycogen and fat deposition, by the enhanced reflection of the muscle 
ultrasound beam (quantified by increased muscle ultrasound density (MUD)) (Maurits et al 
2003, 2004; Pillen et al 2007, 2008; Verbeek et al 2012, 2014). In this respect, muscle 
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In children and adults with GSDI and GSDIII subtypes, we aimed to assess and compare 
MUD with other neurophysiologic and clinical neuromuscular disease parameters, involving: 
EMG neurography, dynometry, CK values and subjective neuromuscular complaints. 




Participants – The Medical Ethical Committee of the University Medical Center Groningen, 
The Netherlands, approved the study protocol. After informed consent by the patients and/or 
parents, we included 26 GSD patients (12 children [GSDI: n = 7, median age 8 y, and GSDIIIa: 
n = 5, median age 4 y] and 14 adults [GSDI: n = 8, median age 29 y, and GSDIII: n = 6, median 
age 31 y]). Because adult normative MUD and muscle force data are still incomplete, we 
compared each adult GSD patient with an adult control subject, resulting in 14 matched pairs 
(matched for age, gender and body mass). For clinical patient data involving neuromuscular 
complaints, CK levels and cardiac abnormalities, see Table 1.  
Procedures – In GSD children and adults, we cross-sectionally determined MUD and we 
associated outcomes with both clinical (GSD disease type, age, neuromuscular complaints and 
CK levels) and neurophysiologic (muscle force and EMG–neurography with surface 
electrodes) parameters. All clinical and neurophysiologic assessments were performed at the 
University Medical Center Groningen, University of Groningen, The Netherlands.  
We performed GSD muscle ultrasound recordings using General Electric Healthcare 
LOGIQ 9 (Jiangsu, China) equipment with a M12 L linear transducer. All recordings were 
obtained at standard clinical settings for muscle ultrasound: B-mode, gain (47 dB), dynamic 
range (DR 69), compression and time gain (neutral position). We used a linear transducer (14 
MHz) and three focal points. For standardization purposes and reproducibility, time-gain 
compensation was preset and maintained constant during all assessments (Pillen et al 2006). 
To obtain standardized reference locations, we recorded transverse ultrasound images of the 
quadriceps muscle (probe placement halfway between trochanter major and lateral knee joint 
cleft) and tibialis anterior muscle (probe placement at one-third from the inferior part of the 
patella and the lateral malleolus) in supine position. We obtained transverse ultrasound images 
of the calf muscle (probe placement at the maximal circumference) in prone position. For 
muscle ultrasound assessment of the biceps muscle, we placed the probe halfway between the 
acromion and antecubital crease in a resting arm position (Maurits et al 2003).  
In accordance with previously published techniques (Maurits et al 2003, 2004), we 
assessed MUD of the biceps, quadriceps, calf (gastrocnemius and/or soleus) and tibialis 
anterior muscles. As metabolic diseases (including GSD), are likely to affect both sides of the 
body symmetrically, we systematically assessed MUD on the left side of the body (in 
accordance with Maurits et al 2003). For descriptions of the applied quantification technique, 
see Brandsma et al (2012, 2014), Sival et al (2011) and Verbeek et al (2012, 2013, 2014).  
In accordance with a standardized technique and protocol, we assessed muscle force in 
standardized positions (Beenakker et al 2001; van der Ploeg et al 1991). We determined 
unilateral (left) muscle force with a hand-held dynamometer (Type CT 3001, C.I.T. Technics, 
Groningen, Netherlands). We expressed pediatric muscle force as Z-scores of normative values 
(Beenakker et al 2001). Because dynamometry requires sufficiently reliable and active 
participation, dynamometry outcomes are considered as 
 reliable from pre-school age onward (i.e., in children older than 4 y). Because of age 
limitations for 4 of 5 GSDIII children included (i.e., ≤ 4 y) and the lack of a control value for 
the remaining extremely overweight child (weight-to-length ratio >+3 SD), we cannot provide 
reliable dynamometry data in these 6 GSDIII children.  
In consideration of the incomplete adult normative muscle force data, we compared 
muscle force between 14 GSD and control patients (as matched pairs; matched for age, gender 
and body mass). We characterized the distribution of muscle force by determining summed 








abductors, elbow flexors, elbow extensors (arms), hip abductors, hip flexors, knee flexors and 
knee extensors (legs). Distal muscles include wrist extensors, three-point grip (arms) and foot 
dorsal-flexors (legs). Total muscle force is calculated as the summed muscle force of all 
proximal and distal muscles (Beenakker et al 2001).  
Electromyography (neurography) was non-invasively performed using bipolar surface 
electrodes at a thermostatically controlled room temperature (Viking IV, Nicolet, Care Fusion, 
Houten, Netherlands). EMG–neurography parameters involved motor nerve conduction, speed 
and amplitude of the median, radial, ulnar and peroneal nerves, including F-responses and 
sensory conduction velocities of median and peroneal nerves.  
Before combined presentation of neuromuscular outcome parameters in GSDIa and 
GSDIb patients, we checked for potentially significant differences (non-significant). As 
neuromuscular involvement may differ between the GSDIIIa and GSDIIIb phenotypes (see 
Introduction), we provide a separate neuromuscular data set for each GSDIII subgroup.  
 
Statistical analysis – We processed data with SPSS Statistics Version 20 (IBM, Armonk, NY, 
USA). We expressed pediatric MUD and muscle force outcomes as Z-scores of normal values 
(both for individual as for summed scores) (Beenakker et al 2001). As muscle force and MUD 
data were not normally distributed (as assessed by Q–Q plots and the Shapiro–Wilk test), we 
compared adult GSD patients and controls using the Wilcoxon signed-rank test. We associated 
MUD with age and CK levels using non-parametric bivariate correlations (Kendall’s t). The 




Glycogen storage disease type I 
 
Clinical data – For all 15 GSDI patients (7 children and 8 adults) assessed, EMG (neurography) 
results were within the normal range (with respect to sensory and motor conductance velocities 
and amplitudes; for normal values, see Kimura [1989]). GSDI children and adults had normal 
blood CK concentrations and no cardiac symptoms (Table 1). Three of seven GSDI children 
and none of 8 GSDI adults experienced neuromuscular complaints interfering with daily life, 
such as (difficulties in climbing stairs, walking or swimming) (Table 1). We observed no 
association between elevated CK levels and neuromuscular complaints (p = 0.94).  
MUD and muscle force in GSDI children – Children with GSDI had elevated MUD 
values (median Z-score in comparison with normative values: 3.3 SD, range: 0.2– 7.8 SD), 
with significantly higher (p < 0.05) MUD values in proximal than distal muscles (i.e., 
myopathic distribution) (Fig. 1). GSDI children had arm and leg muscle weakness (median: -
0.7 SD, range: -3 to 1.8 SD), with significantly more pronounced muscle weakness in proximal 
than distal muscles: median of -2.3 SD (range: -3.7 to -1.6 SD) versus median of 0.4 SD (range: 
-1.6 to 2.4 SD), respectively. In GSDI children, we observed no association between MUD 
outcomes and elevated CK levels (p = 0.70).  
 
MUD and muscle force in GSDI adults – Comparison of MUD between GSDI adults (median: 
103, range: 67–132) and GSDI children (median: 107, range: 76–141) revealed no significant 
differences (Fig. 2). Comparison of MUD between GSDI adults and (age-, gender- and body 
mass-matched) controls revealed no significant differences, despite a tendency (p = 0.09) 
toward higher proximal MUD outcomes in GSDI adults. In GSDI adults, there was no 
significant association between MUD and age (data not shown). Comparison of muscle force 
between GSDI adults and matched controls revealed more muscle weakness in GSDI adults, 
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Glycogen storage disease type I 
 
Clinical data – For all 15 GSDI patients (7 children and 8 adults) assessed, EMG (neurography) 
results were within the normal range (with respect to sensory and motor conductance velocities 
and amplitudes; for normal values, see Kimura [1989]). GSDI children and adults had normal 
blood CK concentrations and no cardiac symptoms (Table 1). Three of seven GSDI children 
and none of 8 GSDI adults experienced neuromuscular complaints interfering with daily life, 
such as (difficulties in climbing stairs, walking or swimming) (Table 1). We observed no 
association between elevated CK levels and neuromuscular complaints (p = 0.94).  
MUD and muscle force in GSDI children – Children with GSDI had elevated MUD 
values (median Z-score in comparison with normative values: 3.3 SD, range: 0.2– 7.8 SD), 
with significantly higher (p < 0.05) MUD values in proximal than distal muscles (i.e., 
myopathic distribution) (Fig. 1). GSDI children had arm and leg muscle weakness (median: -
0.7 SD, range: -3 to 1.8 SD), with significantly more pronounced muscle weakness in proximal 
than distal muscles: median of -2.3 SD (range: -3.7 to -1.6 SD) versus median of 0.4 SD (range: 
-1.6 to 2.4 SD), respectively. In GSDI children, we observed no association between MUD 
outcomes and elevated CK levels (p = 0.70).  
 
MUD and muscle force in GSDI adults – Comparison of MUD between GSDI adults (median: 
103, range: 67–132) and GSDI children (median: 107, range: 76–141) revealed no significant 
differences (Fig. 2). Comparison of MUD between GSDI adults and (age-, gender- and body 
mass-matched) controls revealed no significant differences, despite a tendency (p = 0.09) 
toward higher proximal MUD outcomes in GSDI adults. In GSDI adults, there was no 
significant association between MUD and age (data not shown). Comparison of muscle force 
between GSDI adults and matched controls revealed more muscle weakness in GSDI adults, 
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for summed-arm (p < 0.02), summed-proximal (p < 0.02) and summed-total (p < 0.05) muscles. 
Comparison of muscle weakness between GSDI adults and GSDI children revealed a similar 
outcome, according to a myopathic (proximal > distal, p < 0.05) distribution. There was no 
significant association between MUD and blood CK values in GSDI adults (p = 0.54). 











1 Ia 15 F + +1 None 44 
2 Ia 8 F + - None 86 
3 Ia 16 F + +2 None 57 
4 Ia 6 M + +3 None 104 
5 Ia 17 F + - None 71 
6 Ia 8 M + - None X 
7 Ib 6 F + - None 51 
8 IIIa 3 M - - None 128 
9 IIIa 2 M - - None 466 
10 IIIa 4 M - +3 None 355 
11 IIIa 8 M - +3 CH 981 
12 IIIa 4 M - - None 169 
13 Ia 23 F + - None 85 
14 Ia 26 M + - None 78 
15 Ia 41 F + - None 27 
16 Ia 31 M + - None 72 
17 Ia 34 M + - None 56 
18 Ia 26 F + - None 37 
19 Ia 42 F - - None 87 
20 Ib 18 M + - None X 
21 IIIa 25 F + +2, 4 CH 1823 
22 IIIa 31 F + +2, 4 CH 1093 
23 IIIa 33 F + +2, 4 HOCM 1167 
24 IIIa 31 F + +2, 4 CH 1332 
25 IIIb 30 M + +5 None 56 
26 IIIb 42 F + - None 162 
CH = cardiac hypertrophy (i.e., hyperplasia of the left ventricular posterior and interventricular walls); CK = 
creatine kinase; EMG = electromyography; GSD = glycogen storage disease; HOCM = hypertrophic 
cardiomyopathy (i.e., CH in association with decreased ejection fraction); - = no complaints or abnormalities; X 
= missing data. 
1 Impaired achievement compared with classmates.  
2 Difficulty in climbing stairs.  
3 Walking longer than 3 min.  
4 Walking longer than 20 min.  
5 Swimming longer than 15 min. 
Glycogen storage disease type III 
Clinical data – All seven GSDIII patients assessed (1 child and 6 adults) had normal EMG 
results with respect to sensory and motor conductance velocities and amplitudes. Blood CK 
concentrations were increased in 3 of 5 GSDIIIa children (median: 420 U/L, range: 128–981 
U/L) and in 4 of 4 GSDIIIa adults (median: 1249 U/L, range: 1093–1823 U/L) (Table 1). Two 
of five GSDIII children and 5 of 6 GSDIII adults (GSD- IIIa: n = 4, GSDIIIb: n = 1) experienced 
neuromuscular complaints. Cardiac abnormalities occurred in one GSDIIIa child and in 4 
GSDIIIa adults (Table 1). Elevated CK levels (.200 U/L) concurred with neuromuscular 
complaints in 2 of 3 GSDIII children and in all 4 GSDIII adults.  
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MUD and muscle force in GSDIII children – Children with GSDIII had moderately increased 
MUD values (median Z-scores in comparison with normative data: 1.7 SD, range: -0.9 to 3 
SD), with significantly higher MUD in proximal than distal muscles (p < 0.05, for Z-scores of 
proximal muscles) (Fig. 1). Comparison of MUD values between GSDI children and GSDIII 
children revealed significantly higher MUD values in GSDI children for all except calf 
muscles: median of 110, (range: 41–131) versus median of 89 (range: 85–93), respectively (p 
< 0.05) (Fig. 3). Because of age and/or body mass limitations of all 5 GSDIII children included, 
we cannot provide reliable muscle force data in this group (i.e., too young).  
MUD and muscle force in GSDIII adults – GSDIIIa adults had significantly higher (p < 0.05) 
MUD values than GSDIIIa children: median of 118 (range: 113–136) versus a median of 90 
(range: 85–93), respectively, for all muscles assessed (Fig. 4). In GSDIIIa adults, MUD was 
higher in proximal than distal leg muscles: median of 118 (range: 113–144) versus median of 
113 (range: 90–124) (p = 0.046). Comparison of MUD values between GSDIII adults and 
matched controls revealed higher MUD values in GSDIII adults, for all assessed leg muscles 
(i.e., quadriceps, tibialis anterior and calf muscles). Comparison of MUD values between 9 
GSDIIIa and 2 GSDIIIb patients, suggested lower MUD values in GSDIIIb patients (Fig. 5, no 
statistics applicable). Comparison of MUD values between GSDIII and GSDI adults revealed 
significantly higher (p < 0.05) values in GSDIII adults for calf muscles (median of 132 [range: 
101–144] vs. median of 97 [range: 83–130] and tibial anterior muscles median of 129 [range: 
121–146] vs. median of 104 [range: 82–119]) (Fig. 6). 
Cross-sectional MUD in GSDIII patients revealed a positive association with age (age 
range: 2–42 y) for biceps (r = 0.83), quadriceps (r = 0.71) and tibialis anterior (r = 0.74) muscles 
(Fig. 7). Additionally, MUD results in GSDIII patients tended to reveal a positive association 
with blood CK levels (median: r = 0.42, range: 0.16–0.49), although not statistically significant. 
Adults with GSDIII had muscle weakness of the shoulder abductors, elbow extensors, 
finger flexors, knee extensors, summed-arm and summed-proximal muscles (all p’s < 0.05). 
Comparison of muscle force between GSDI adults and GSDIII adults revealed more muscle 
weakness in GSDIII adults involving elbow extensors, summed-arm and summed-distal 
muscles of both arms and legs (all p were < 0.05). Comparison of muscle force between 
GSDIIIa (n = 4) and IIIb (n = 2) subtypes tended to reveal more muscle weakness in the former 
(statistical analysis not applicable because of small numbers).  
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for summed-arm (p < 0.02), summed-proximal (p < 0.02) and summed-total (p < 0.05) muscles. 
Comparison of muscle weakness between GSDI adults and GSDI children revealed a similar 
outcome, according to a myopathic (proximal > distal, p < 0.05) distribution. There was no 
significant association between MUD and blood CK values in GSDI adults (p = 0.54). 
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Figure 1 Muscle ultrasound density (MUD) of biceps and quadriceps muscles in children with glycogen storage 
disease (GSD), types I and IIIa. MUD is expressed as Z-scores of normal values. In GSDI children, MUD is 






Figure 2 Muscle ultrasound density (MUD) of arm and leg muscles in patients with glycogen storage disease 










Figure 3 Muscle ultrasound density (MUD) of arm and leg muscles in children with glycogen storage disease 





Figure 4 Muscle ultrasound density (MUD) of arm and leg muscles in patients with glycogen storage disease 
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Figure 5 Muscle ultrasound density (MUD) of leg muscles in adults with glycogen storage disease (GSD) type 
III compared with controls. GSDIII adults revealed significantly higher MUD outcomes than age-, gender- and 
body mass- matched controls. MUD outcomes in two GSDIIIb patients are separately indicated (dotted line). 
Figure 6 Muscle ultrasound density (MUD) of arm and leg muscles in adults with glycogen storage disease 
(GSD) types I and III. Distal leg muscles of GSDIII adults revealed significantly higher MUD outcomes than 
distal leg muscles of GSDI adults (distal leg muscles refer to tibialis anterior and calf muscles). 
95 
Figure 7 Relation between muscle ultrasound density (MUD) and age in patients with glycogen storage disease 
(GSD) type III. From child- to adulthood, GSDIII patients revealed a positive association between MUD and age 
(for biceps, quadriceps and tibial anterior muscles). 
Discussion 
In GSD patients, dietary and metabolic treatments have improved longevity, resulting in the 
clinical need for more consistent neuromuscular surveillance and support. In pediatric and adult 
‘‘hepatic’’ and ‘‘myopathic’’ phenotypes, long-term information on neuromuscular 
involvement is still incomplete. In children with both ‘‘hepatic’’ and ‘‘myopathic’’ phenotypes 
(GSDI and GSDIII), we observed myopathy. In adult ‘‘hepatic’’ GSDI patients, myopathy 
stabilized, whereas in adult ‘‘myopathic’’ GSDIII patients, myopathy progressed with age.  
In the assessed GSDI and GSDIII patients, we observed no neuropathic EMG 
alterations, as indicated by our EMG ‘‘neurography’’ data (by surface electrodes). Absent 
EMG ‘‘neurography’’ abnormalities are in contrast with previously published EMG 
‘‘myography’’ data (obtained with invasive needle electrodes), indicating myopathy in both 
GSDI and GSDIII patients (Hobson-Webb et al 2010). From the latter perspective, we reasoned 
that the non-invasive muscle ultrasound technique could provide more myopathic information 
for each GSD subtype and age category. To the best of our knowledge, systematic muscle 
ultrasound data have not been obtained in GSD patients before.  
In both GSDI and GSDIII children, muscle ultrasound and dynamometry data revealed 
myopathic involvement, with a proximal to distal (‘‘myopathic’’) distribution. Although 
pediatric MUD parameters appeared more strongly affected in GSDI than in GSDIII children, 
direct comparisons should be avoided. Especially because GSDIII patients manifested ‘‘MUD 
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Figure 5 Muscle ultrasound density (MUD) of leg muscles in adults with glycogen storage disease (GSD) type 
III compared with controls. GSDIII adults revealed significantly higher MUD outcomes than age-, gender- and 
body mass- matched controls. MUD outcomes in two GSDIIIb patients are separately indicated (dotted line). 
Figure 6 Muscle ultrasound density (MUD) of arm and leg muscles in adults with glycogen storage disease 
(GSD) types I and III. Distal leg muscles of GSDIII adults revealed significantly higher MUD outcomes than 
distal leg muscles of GSDI adults (distal leg muscles refer to tibialis anterior and calf muscles). 
95 
Figure 7 Relation between muscle ultrasound density (MUD) and age in patients with glycogen storage disease 
(GSD) type III. From child- to adulthood, GSDIII patients revealed a positive association between MUD and age 
(for biceps, quadriceps and tibial anterior muscles). 
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age-related-ness’’ from childhood onward (Fig. 7) and because GSD- III children were younger 
than GSDI children, outcomes should also be interpreted with respect to the effect of age. Even 
though elevated MUD values coincided with muscle weakness, neuromuscular complaints 
were expressed by only a minority of the children (i.e., GSDI: 43%, GSDIII: 40%). As pediatric 
MUD alterations were not related to blood CK levels, we may deduce that the non-invasive 
muscle ultrasound technique has the potential to reveal early myopathic alterations, even in the 
absence of: neurographic EMG abnormalities (which are considered to be late [Kishnani et al 
2014]), CK elevations and/or neuromuscular complaints. 
In young children with the ‘‘hepatic’’ GSDI phenotype, the pathogenesis of the 
pronounced myopathic alterations remains unclear. Although beyond the scope of the present 
study, it is tempting to speculate that upregulated muscle enzyme activity could be involved. 
In the classic GSDI disease model, glucose production is generally considered as absent. 
However, stable isotope studies have indicated that these patients can have glucose production 
rates as high as 60% of normal (Huidekoper et al 2010). In GSDI patients, one might thus 
speculate that metabolic upregulation of muscle enzyme activity (for instance, by the 
debranching enzyme a-glucosidase muscle and/or glucose-6-phosphatase b [Shieh et al 2002]) 
could contribute to whole-body glucose production. In healthy patients, such endogenous 
glucose production has been found to decrease with age (i.e., from infancy to childhood to 
adulthood) (Zijlmans et al 2009). Analogously, one might hypothesize that myopathy in young 
GSDI children could reflect muscle energy deficiency during this critical period. The 
aforementioned myopathic alterations in children are contrasted by the ‘‘stabilized’’ 
neuromuscular parameters in GSDI adults. In adult GSDI patients, the ‘‘stabilized’’ 
neuromuscular parameters may be explained by restoration of metabolic control and decreased 
demands for endogenous glucose production. It is hoped future metabolic GSD studies can 
elucidate these potential mechanisms.  
In contrast to the ‘‘stabilized’’ myopathic parameters of GSDI adults, myopathic 
parameters deteriorated with age in GSDIII adults (positive MUD–age relationship from 
childhood to adulthood). This observation appears in line with the previously described 
GSDIIIa disease course (Dagli et al 2012), gradually evolving from pediatric fasting 
intolerance and hypoglycemia to chronic neuromuscular pathology in adults. Although it is 
tempting to speculate that increased muscle glycogen and fat deposition could underlie all these 
age-related alterations (van Adel & Tarnopolsky 2009), other influences, such as blood vessel 
pathology, should also be considered (Cornelio et al 1984; Kiechl et al 1999; Wary et al 2010). 
In adult GSDIII patients, we observed concurring age-related MUD elevations, increased blood 
CK concentrations and other neuromuscular symptoms. These neuromuscular symptoms 
involved exercise intolerance, cardiac involvement and myopathic muscle weakness, with 
progressive extension to more muscle groups (gradually affecting the tibialis anterior too). It 
was recently reported that for GSDIIIa patients, the combination of underlying muscle 
weakness and energy deficiency is likely to result in exercise intolerance (Preisler et al 2013). 
After glucose infusion, Preisler et al (2013) reported improved exercise tolerance in association 
with increased mitochondrial fatty acid oxidation. In line with Preisler et al (2013), our 
observations suggest the potential for dietary lipid administration in patients with acute and 
chronic GSDIIIa disease (Derks & van Rijn 2015). In addition to the current strategy of high-
protein diets (Derks & Smit 2015), it may be speculated that stimulation of fatty acid oxidation 
could exert a beneficial therapeutic effect by bypassing blocked carbohydrate metabolism 
(Derks & van Rijn 2015). It is hoped that future GSDIII research may elucidate whether dietary 
therapies (such as the Atkins diet [Mayorandan et al 2014], ketogenic diet, medium-chain 
triglyceride enrichment or pharmacologic agents) could have a beneficial effect on 








We recognize several weak points in this study. First, we obtained cross-sectional data, 
prohibiting delineation of individual disease trajectories. Second, because GSDI and GSDIII 
subtypes are relatively rare, we could only assess a limited number of patients. Third, we 
deliberately presented adult GSD data with reference to healthy control data (as matched pairs), 




In GSD, muscle ultrasonography can provide an excellent, non-invasive tool for clinical 
monitoring of neuromuscular pathology. In children, both ‘‘hepatic’’ and ‘‘myopathic’’ GSD 
phenotypes were associated with myopathic symptoms; however, myopathy stabilized in adult 
‘‘hepatic’’ (GSDI) phenotypes, whereas myopathy progressed in adult ‘‘myopathic’’ (GSDIII) 
phenotypes. Future neuromuscular GSD studies may elucidate whether and, if so, how muscles 
compensate for physical demands when metabolic control is chronically altered. In 
consideration of the improved longevity of GSD patients, we conclude that non-invasive 
muscle ultrasound can provide an important contribution to neuromuscular surveillance 
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The focus of this thesis was to investigate the natural course, and especially the clinical, 
biochemical and genetic aspects of glycogen storage disease type III (GSDIII). In GSDIII, 
glycogen storage is found in liver, (cardiac-) muscle, and nervous tissue (Laforêt et al 2012). 
Differences in tissue expression of the deficient GDE only partially explain the existence of 
various subtypes of GSDIII of which GSDIIIa (expressed in liver, skeletal muscle and 
sometimes heart muscle) and GSDIIIb (only expressed in liver tissue) are the most frequent 
subtypes (Wolfsdorf & Weinstein 2003). Due to the rarity of the disease, long-term experience 
with severe secondary GSDIII-related complications in different metabolic centres is limited. 
Until recently, no data were available on the clinical course and the associated complications 
of the disease. In summary, the studies in this thesis generated the following results: 
Summary 
Chapter 1: Provides a literature review, including a disease summary and description of 
hallmarks of the disease. 
Chapter 2: Mutation analysis was performed in GSDIII patients using the DGGE method, 
which had not previously been applied on the AGL gene. We studied if this procedure is a 
reliable mutation analysis method to diagnose GSDIII. Also, we described novel AGL 
mutations among GSDIII populations. Furthermore, we studied genotype-phenotype 
correlation as the result of the mutation analysis may give an indication of the GSDIII subtype 
and clinical course. 
Chapter 3: The appearance of age-related complications in the international literature, and 
the absence of an evidence-based consensus in dietary and pharmacological treatment, created 
the need for a multi-center international retrospective study (ISGSDIII) in which the natural 
course was investigated in a large group of patients. The aim of the ISGSDIII was to increase 
knowledge of diagnosis, course, and complications of GSDIII patients. Chronic complications 
involved the liver in 11%, cardiomyopathy in 52%, reduced exercise tolerance in 52%, muscle 
weakness 71%, and type 2 diabetes mellitus was diagnosed in 9% (of the adult patients). 
Chapter 4: Hypertriglyceridaemia and hypercholesterolaemia were common in children 
under 3 years of age, with hypertriglyceridaemia correlating negatively with age. We 
questioned therefore, if the presence of hyperlipidaemia during childhood could put GSDIII 
patients at risk for early cardiovascular disease. However, no indications for an increased 
incidence of atherosclerosis-related complications were found in ISGSDIII (chapter 3). 
Chapter 5: Cardiac hypertrophy and severe heart failure was reversed in an adult GSDIIIa 
patient by low-calorie high-protein adjustments, deferring and ultimately even preventing the 
need for cardiac transplantation. 
Chapter 6: Progression of muscular disease in GSDIII patients is associated with increased 
muscle ultrasound density and decreased muscle force (with a myopathic distribution). 
105 
Discussion 
Since the first description of GSDIII major progress has been made regarding clinical, 
biochemical, and genetic features which offers diagnostic and management options. Through 
dietary treatment and supportive pharmacological care morbidity and mortality because of 
acute metabolic derangement has decreased. With age and despite dietary management GSDIII 
patients may still develop chronic complications of multiple organs. The main concern of this 
thesis is to present a template regarding the clinical course and complications that may develop 
in the future. 
Major points of interest are: 
o Diagnosis by molecular analysis (in chapter 2 and 3): Most GSDIII patients have unique
AGL genotypes, with an interesting overrepresentation of non-missense mutations are
overrepresented. This is in contrast to most metabolic diseases. Currently, mutation
screening methods and single-gene sequencing has been largely replaced by gene panel
sequencing methods (Wang et al 2013; Vega et al 2016). Invasive diagnostic procedures
such as liver biopsies have been almost completely abolished in current clinical GSD
workups.
o Chronic complications (chapter 3 and 6): Morbidity at a later age may be very debilitating.
One example is, that we observed type II diabetes in 10% of adult patients which causes
paradox aims for the management of GSDIII (Oki et al 2000). Also, muscular involvement
in GSDIIIa may cause severe morbidity which is progressive into adulthood, causing
significant impairment in daily life. A similar progressive pattern for loss of muscle force
in GSDIII patients was recently found in a cross-sectional retrospective single site study by
Decostre et al in 2016. GSDIII-related cardiac complications (chapter 5) mostly present as
cardiac hypertrophy, which may develop into cardiomyopathy. Dietary interventions can
be very beneficial when metabolic control is compromised in daily life. However, when
cardiac complications firstly develop in adulthood, screening for a second genetic substrate
predisposing patients for cardiomyopathy may be useful (especially in consanguine
families) (Dewey et al 2016). A correlation between the chronic complications and
metabolic control (as for instance for hepatic adenomas in GSDI) could not be established.
o Hyperlipidaemia (chapter 4) is a common finding in young GSDIII patients, and the
incidence may decrease with age and thus less variable blood glucose concentrations. Based
on the ISGSDIII cohort, later in adolescent and adult life, it does not cause significant
clinical cardiovascular events.
Future Perspectives 
The studies presented in this thesis allow to speculate about the following future perspectives 
regarding some clinical hallmarks, management and follow-up:  
o There is significant heterogeneity between GSD patients necessitating personalised
medicine. Ideally, treatment evaluation is not limited to the hospital setting. The real world
setting of the patients may even provide a better picture of treatment effectiveness and
technically, telemedicine (which includes eHealth and mHealth) can integrate relevant
parameters and facilitate a communication platform between patients with rare diseases and
health care providers with expertise. Therefore, a mobile GSD communication platform is
being developed to facilitate home-site metabolic monitoring and evaluation of dietary
interventions by collecting biochemical, physiological and dietary follow-up parameters
for individual GSD patients.
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o New treatment strategies are warranted for both acute and chronic GSD (III) patient 
problems. Examples may include a modified starch (Glycosade®), dietary interventions 
with ketogenic diets and/or MCT-supplementation in selected cases (Valayannopoulos et 
al 2011; Brambilla et al 2014; Mayorandan et al 2014), ketone bodies (Cox et al 2016), 
gene therapy (Sun et al 2015), alpha-glucosidase replacement therapy (Sun et al 2013) and 
rapamycin (Yi et al 2014). 
o Maintaining stable glucose concentrations, and thus good metabolic control, is the centre 
pillar of the dietary treatment of hepatic GSDs. Extended release cornstarch (Glycosade®) 
has been developed (Bhattacharya et al 2007; Correia et al 2008; Nalin et al 2015) and 
recently, a prospective, randomised double blind crossover clinical trial (ClinicalTrials.gov 
Identifier NCT02318966) has been initiated. The Glyde trial aims to establish whether 
Glycosade® improves short-term and long-term outcomes for patients with GSD compared 
to the traditional uncooked cornstarch. 
o Myopathy is a common disabling phenotype in adulthood despite dietary management. 
Recently, acute nutritional ketosis in exercise was studied in humans and was found to 
enhance muscle mitochondrial function in athletes (Cox et al 2016). An interventional 
study has been started to evaluate the effect of acute ketosis on muscular performance in 
adult GSDIIIa patients (ClinicalTrials.gov Identifier NCT03011203).  
o Glucose homeostasis in GSDIII patients remains delicate even into adulthood, development 
of secondary insulin resistance and insulin-dependent diabetes mellitus in older GSD III 
patients may complicate treatment even more (Dewey et al 2016; Lee et al 1997). Related 
to this, lipid metabolism seems to be perturbed as well, particularly in younger patients. In 
this perspective, the development of diabetes mellitus type II in 10% of the GSD III patients 
could be viewed in the light of the metabolic syndrome.  
o Animal models have been proven to be very useful in research on disease pathophysiology 
and the testing of novel therapeutic options. Two GSDIIIa animal models have been 
developed in recent years, a canine (Yi et al 2012; Brooks et al 2016) and mouse model 
(Liu et al 2014; Pagliarani et al 2014). The canine model of GSDIII has a homozygous 
frameshift mutation in exon 32 in AGL leading to the deletion of 126 amino acids, causing 
a GSDIIIa phenotype which was confirmed by enzyme activity measurements in muscle 
and liver tissue. Biochemically, normolipidaemia was observed in this model in contrast to 
human GSDIIIa, liver- and muscle enzymes however (AST, ALT, AP and CK) were 
elevated (Yi et al 2012). In follow-up, these values decreased and the dogs showed liver 
and muscle fibrosis, matching human GSDIIIa (Brooks et al 2016). Two mouse models 
have been developed, one by removing the exons after exon 5 in AGL, the other by the 
deletion of exons 32-34 (Liu et al 2014; Pagliarani et al 2014). These models showed severe 
glycogen accumulation in liver and muscle tissue, even in the central nervous system and 
the diaphragm. Also in these models, normolipidaemia was observed. While both models 
have most of the hallmark features of GSDIIIa, only the canine model has been used for 
testing experimental therapeutic options. In the canine GSDIIIa model rapamycin (an 
inhibitor of mTOR) has been shown to reduce glycogen accumulation in muscle cells and 
prevent hepatic fibrosis suggesting therapeutic possibilities for GSDIIIa patients (Yi et al 
2014). 
o There is a need for collaborative international patient registries for rare diseases, including 
hepatic glycogen storage diseases (like GSDIII). To study and answer remaining questions 
regarding certain clinical features and dietary/pharmacological treatment in the future, a 
prospective database is warranted which focusses on hepatic GSDs in general with the 








o The recent development and national endorsement of expertise centres for very rare 
diseases (such as hepatic glycogen storage diseases) and the construction of formal 
international networks (such as the European Reference Network for Hereditary Metabolic 
Diseases (MetabERN)) may promote the development of evidence based treatment 
guidelines, patient empowerment and governance structures.  
o There is a need to structure and prioritise future research agendas. In the last decade, the 
James Lind Alliance (www.jla.nihr.ac.uk) has facilitated Priority Setting Partnerships 
(PSPs) for several medical conditions (Partridge et al 2004). To date these PSPs have 
focussed on common disorders and they have been organised on a national level. This year 
a PSP will be created to formulate the Top 10 priorities for future research for children and 
adults with hepatic GSD. This will be the first international, multilingual PSP focussing on 
ultra-rare inherited metabolic diseases. It is expected that the outcome will promote patient 
empowerment in scientific research and that research topics that are most important to the 
patients may be addressed sooner and more effectively.  
 
In conclusion, ISGSDIII and the other studies in this thesis have contributed to an expansion 
of the knowledge on the clinical course of GSDIII and its related complications. Also, the 
identification of lapses in knowledge through ISGSDIII have given room for the development 
of novel studies and initiatives to fill these gaps. Therefore, monogenetic GSDs already have, 
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Dit proefschrift had als doel om het natuurlijk beloop te belichtten van 
glycogeenstapelingsziekte type III (GSDIII), en dan vooral de klinische, biochemische en 
genetische aspecten. Bij GSDIII-patiënten stapelt zich glycogeen in de lever, (hart-) 
spierweefsel, en zenuwweefsel. Verschillen in de weefselexpressie zijn echter slechts een 
gedeeltelijke verklaring voor het bestaan van verschillende subtypes van GSDIII. Hiervan zijn 
GSDIIIa (wat tot uitdrukking komt in de lever, skeletspieren en soms het hart) en GSDIIIb (wat 
alleen tot uitdrukking komt in de lever) de meest voorkomende subtypes. Omdat GSDIII een 
zeer zeldzame ziekte is, is er weinig lange-termijn ervaring met de secundaire complicaties – 
zelfs in grote metabole centra. Tot voor kort waren er tevens slechts weinig wetenschappelijke 
data beschikbaar met betrekking tot het natuurlijk beloop en deze secundaire complicaties. In 
dit proefschrift hebben we specifiek naar het beloop en deze complicaties gekeken, en 
samengevat zijn dit de resultaten: 
• Hoofdstuk 1 is een samenvatting van de bekende literatuur, waarbij een samenvatting
wordt gegeven van de belangrijkste kenmerken van het ziektebeeld.
• In hoofdstuk 2 presenteren we een mutatieanalyse methode (DGGE) voor het AGL-gen,
die voorheen nog niet was toegepast. We hebben deze methode toegepast in een
populatie GSDIII-patiënten, en hebben onderzocht of DGGE betrouwbaar is om het
AGL-gen mee te analyseren. Tevens worden in dit hoofdstuk nieuwe mutaties
beschreven, en hebben we gekeken of er een relatie is tussen de gevonden mutaties
(inclusief de reeds bekende mutaties) en het klinische fenotype.
• Hoofdstuk 3 beschrijft de resultaten van een multicenter internationaal retrospectief
onderzoek naar het natuurlijk beloop van GSDIII. Dit onderzoek werd gedaan in de (tot
nu toe) grootste groep GSDIII-patiënten, en had als doel om de kennis over de
diagnosestelling, het beloop, en de complicaties uit te breiden. De meest frequente
complicaties betroffen de lever (bij 11% van de patiënten), cardiomyopathie (52%),
lage inspanningstolerantie (52%), spierzwakte (71%), en diabetes mellitus type 2 (9%,
van de volwassen patiënten).
• In hoofdstuk 4 gaan we nader in op de hypertriglyceridemie en hypercholesterolemie
die veel voorkomt bij GSDIII-patiënten, vooral bij kinderen onder de 3 jaar. Hierbij
correleerde hypertriglyceridemie negatief met leeftijd. Om deze reden kwam de vraag
naar voren of hyperlipidemie op jonge leeftijd het risico op hart- en vaatziekten op
latere leeftijd verhoogde. Er werden echter in hoofdstuk 3 geen aanwijzingen gevonden
dat artherosclerose bij volwassen GSDIII-patiënten een veelvoorkomende complicatie
is.
• In hoofdstuk 5 beschrijven we de casus van een volwassen GSDIIIa-patiënt die een
ernstige hypertrofische cardiomyopathie ontwikkelde en daardoor in aanmerking kwam
voor een harttransplantatie. De cardiomyopathie kon echter succesvol behandeld
worden met een calorieën-beperkt eiwitrijk dieet, waardoor de hypertrofie terugliep en
een harttransplantatie niet nodig was.
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• De focus in hoofdstuk 6 ligt op de skeletspieren waarbij we middels het meten van de
echogeniteit van de spieren en het doen van krachtmetingen al op jonge leeftijd
myopatische veranderingen bij GSDIII-patiënten konden vaststellen.
Sinds GSDIII voor het eerst werd vastgesteld in het midden van de vorige eeuw is er een 
enorme vooruitgang geboekt wat betreft de diagnostiek, behandeling, en het monitoren van de 
effectiviteit van de behandeling. Dit proefschrift dient als een blauwdruk voor het beloop van 
GSDIII in een grote groep patiënten, iets wat nog nooit eerder is gedaan. Op basis van deze 
blauwdruk kan een duidelijker toekomstbeeld gegeven worden aan patiënten en behandelaars. 
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ALAT    alanine aminotransferase  
ASAT    aspartate aminotransferase 
BMD     bone mineral density 
BMI     body mass index 
CGDF    continuous gastric drip feeding 
CK     creatine kinase 
CRF     case record form 
CSCE     conformation sensitive capillary electrophoresis 
CVD     cardiovascular disease 
DGGE    denaturing gradient gel electrophoresis 
DM2     type 2 diabetes mellitus 
EMG     electromyography 
ESGSDI    european study on glycogen storage disease type I 
ESP     exome sequencing project 
GDE     glycogen debranching enzyme 
GSD     glycogen storage diseases 
GSDI     glycogen storage disease type I 
GSDIII    glycogen storage disease type III 
HCC     hepatocellular carcinoma 
HTX     heart transplantation 
ISGSDIII    international study on glycogen storage disease type III 
IVS     intraventricular septum 
LD     limit dextrin 
LVH     left ventricular hypertrophy 
MUD     muscle ultrasound density 
NYHA    new york heart association 
PSP     priority setting partnership 
PW     posterior wall 
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Dit proefschrift is grotendeels het resultaat van de samenwerking met collega's uit binnen- en 
buitenland, en ik denk dat tijdens die periode mijn dankbaarheid en enthousiasme al tot uiting 
zijn gekomen. Onderzoek zoals in dit proefschrift beschreven is echter alleen mogelijk dankzij 
de patiënten (en de ouders), en ik wil hen daarom als eerste bedanken.  
 
De mensen die het onderzoek mogelijk hebben gemaakt wil ik als volgende bedanken. Mijn 
promotor Peter en co-promotor Terry, zonder jullie was dit project nooit tot stand gekomen en 
was het onmogelijk geweest het te completteren. Peter, bedankt voor de ingang die je me gaf 
voor dit onderzoek als wetenschapsstage, en voor het vertrouwen dit uit te mogen bouwen tot 
een promotieproject. De jaren dat ik in het UMCG doorbracht was je altijd beschikbaar voor 
vragen en overleg, en met jouw contacten kon ISGSDIII van de grond komen. Terry, bedankt 
voor je advies en motivatie. De laatste periode ben je een enorme drijfveer geweest achter dit 
project en achter mijn promotie. Met jouw geduld en inzicht werd dit tot een succes. 
 
Without the support, guidance and hospitality of many colleagues from around the globe 
ISGSDIII would not have been possible. Thank you “ISGSDIII team”! I would especially like 
to thank Prof. dr. David Weinstein, who mentored me during my time in Florida and was a 
driving force behind ISGSDIII. You are an amazing example of what one person can do when 
he puts his mind to it and your dedication to progress in the treatment of hepatic GSD will 
prove to be essential to the success of new therapeutic strategies. I also owe a lot of gratitude 
to Dr. Ulrike Steuerwald and Dr. Elaine Murphy for their hospitality and help during my time 
in Tórshavn and London, respectively. I would like to thank the members of the assessment 
committee, Professor dr. Reijngoud, Professor dr. van der Ploeg and Professor dr. Santer for 
their assessment. 
 
Mijn kamergenoten Michelle, Jozien en Janyte: we hebben slechts een jaar samen in de kelder 
van het Triadegebouw doorgebracht maar het was een onvergetelijke tijd. Soms waren er 
lastige dagen maar dankzij jullie ondersteuning en humor was het een "year to remember"! 
 
Dan de paranimfen – Egbert, we hebben elkaar de afgelopen jaren niet veel gezien, en met onze 
drukke banen zal dat lastig blijven. Desondanks ben je altijd een van mijn beste vrienden 
gebleven en is het elke keer dat we elkaar spreken meteen weer als vanouds. Dank dat je er 
altijd bent geweest en gebleven. 
 
Lieve Marleen, jij bent het meest fantastische wat mij ooit is overkomen en degene met wie ik 
altijd samen wil zijn. In mijn promotieperiode zijn we elkaar lang uit het oog verloren, maar 
niet uit het hart. Gelukkig is dat in het afgelopen jaar veranderd, en ik weet dat we nog zoveel 
mooie dingen voor de boeg hebben. 
 
Lieve Sjieuwke Lies en Hessel Jan, jullie zijn over de jaren mijn beste vrienden geworden en 
maken mij altijd aan het lachen, dankzij jullie is het glas altijd halfvol. Lieve papa en mama, 
bedankt dat jullie altijd achter me staan en voor jullie grenzeloze vertrouwen. "Je kan het!" 
kreeg ik altijd weer te horen en dat heeft me gebracht waar ik nu ben. Dankzij dit mantra en de 
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